

Subject Index—Volume 89

No. 1, July 1, pp. 1-228
 No. 2, July 15, pp. 229-474
 No. 3, August 1, pp. 475-714
 No. 4, August 15, pp. 715-938
 No. 5, September 1, pp. 939-1180
 No. 6, September 15, pp. 1181-1412
 No. 7, October 1, pp. 1413-1646

No. 8, October 15, pp. 1647-1868
 No. 9, November 1, pp. 1869-2024
 No. 10, November 15, pp. 2025-2144
 No. 11, December 1, pp. 2145-2326
 No. 11, December 1, Supplement, pp. 2327-2514
 No. 12, December 15, pp. 2515-2686

A

Acquired immunodeficiency syndrome, non-Hodgkin's lymphoma in, stem cell transplant for, 680
 Acute leukemia. *See* Leukemia
 Adenocarcinoma. *See specific sites*
 Africa, Ivory Coast, cancer incidence in, 653
 African Americans
 bladder cancer in, stage at diagnosis of, 1349
 breast cancer outcome in, 2202
 AIDS, non-Hodgkin's lymphoma in, stem cell transplant for, 680
 Alcohol use/abuse
 gastric cancer survival and, 1205
 hepatitis C-related hepatocellular carcinoma and, 53
 Alliance for Lung Cancer Advocacy, Support, and Education (ALCASE), 2510
 Alternative therapies, compliance with standard treatment and, 873
 Alveolar proteinosis, in BCR/ABL negative chronic myeloid leukemia, neutrophil hyperfunction in, 561
 Amenorrhea, after chemotherapy, for osteosarcoma, 1961
 American Cancer Society, prospective cohort study of thyroid cancer, 202
 American College of Surgeons Commission on Cancer, prospective cohort study of thyroid cancer, 202
 American Indians, stage at diagnosis, treatment, and survival in, 181
 9-Aminocamptothecin, for metastatic colorectal cancer, 1699
 Analgesia
 consultation for, outcome of, 920
 morphine in hospice setting and, 220 (letter)
 Angiogenesis, inhibition of
 gene therapy for, 1181
 for prostate cancer, 1329
 Angiosarcoma, schwannoma with, 1577
 Angiotrophic large cell lymphoma, superior vena cava syndrome and, 2515
 Antiangiogenic therapy
 gene therapy in, 1181
 for prostate cancer, 1181, 1329
 Antibody(ies)

anti-CD20, for cutaneous B-cell lymphoma, 1835
 monoclonal
 IMC-C225, inhibition of pancreatic tumor growth by, 74
 for prostate cancer, 1329
 single chain Fv fragment of, in immunofluorescent tumor localization, 1134
 p53, in esophageal cancer, 1677
 Anti-CD20 antibody, for cutaneous B-cell lymphoma, 1835
 Antiemetics, ganisetron vs. ondansetron as, 2301
 Antiestrogen ICI 182,780 (Faslodex), for breast cancer, 817
 Antigen(s). *See also specific antigens*
 CA 19-9, in pancreatic cancer, vs. tissue polypeptide specific antigen, 83
 CA 125, in fallopian tube cancer, prognosis and, 1555
 carcinoembryonic
 in colorectal cancer, prognosis and, 970
 in immunoscintigraphy, for breast cancer, 104
 isolated elevation of, in colorectal cancer, radioimmunoguided surgery for, 1692
 Ki-67
 in breast cancer
 chemotherapy response and, 2145
 prognosis and, 1748
 in Ewing's sarcoma, prognosis and, 783
 in nonsmall cell lung cancer, postoperative survival and, 1457
 p21
 in bladder cancer, prognosis and, 619
 in cervical squamous cell carcinoma, 1300
 in Ewing's sarcoma, prognosis and, 783
 p27^{Kip1}, in gastric cancer, prognosis and, 1684, 2247
 p53. *See* p53
 proliferating cell nuclear
 in congenital sacrococcygeal teratoma, 932
 in verrucous oral cancer, 2597
 prostate specific
 adjusted for transition zone volume, 842
 after radical prostatectomy, 1810

- prostate specific membrane, monoclonal antibodies to, for prostate cancer, 1329
- tissue polypeptide specific, in pancreatic cancer, 83
- Antimicrotubule drugs, for hepatoma, 983
- Antioxidant enzymes, in prostatic intraepithelial neoplasia and cancer, 123
- Apoptosis, in breast cancer, chemotherapy response and, 2145
- Appalachia, breast and cervical cancer mortality in, 1593
- Argyrophilic cell hyperplasia, duodenal carcinoids and, 963
- Arterial embolization, with arterial infusion chemotherapy, for pancreatic cancer, 303
- Arterial infusion chemotherapy, for pancreatic cancer, 303
- Ascorbic acid, accumulation of, in squamous cell carcinoma, 171
- Asian Americans, screening for breast and cervical cancer in, 696
- Asians
- breast cancer in, *BRCA1* mutation and, 811
 - nasal-type natural killer/T-cell and natural killer precursor lymphoma in, 2106
 - in U.S., gastric cancer in, clinical features and survival in, 1183
- Assessment tool(s)
- McGill Quality of Life Questionnaire, 1854
 - M.D. Anderson Symptom Inventory, 1634
 - for symptom distress, 1634
- Astrocytoma, pathologic classification of, 1569
- Auriculotemporal syndrome, botulinum toxin for, 1659
- Australia, melanoma in, time trends of, 1269
- Avascular necrosis of femoral head, in interferon-treated chronic myeloid leukemia, 1482
- B**
- B7 molecules, T-cell proliferation and, in B-cell chronic lymphoproliferative disorders, 1259
- Basal cell carcinoma, clustering of, 1012
- B-cell chronic lymphocytic leukemia, CD44 and intercellular adhesion molecule-1 in, during interferon therapy, 1474
- B-cell chronic lymphoproliferative disorders, T-cell proliferation in, B7 molecules and, 1259
- B-cell lymphoma
- cutaneous
 - anti-CD20 antibody for, 1835
 - central nervous system involvement in, 913
 - telomerase activity in, 445
- bcl-2*
- in breast cancer, chemotherapy response and, 2145
 - in renal cell carcinoma, DNA content and, 1065
- BCNU, resistance to, transforming growth factor- β 1-binding protein and, 850
- Benign breast disease
- cancer risk with hormone replacement therapy and, 2046
 - relaxin-like factor in, 2161
- Benign central neurocytoma, 1111
- Bile ducts, noninvasive/minimally invasive papillary carcinoma of, 508
- Biliary obstruction, from gastric cancer, chemoradiation for, 29
- Biliary papillomatosis, intraluminal iridium-192 for, 69
- Biologic therapy, for prostate cancer, 1329
- Biomarkers. *See* Tumor markers
- Biopsy
- endometrial, diagnostic yield of, 1765
 - image-guided core-needle, in lymphoma, 647
 - lymph node
 - image-guided core-needle, in Hodgkin's disease, 647
 - sentinel node
 - in breast cancer
 - computer simulations for, 2187
 - false negative, after preoperative chemotherapy, 2187
 - in melanoma
 - frozen section analysis of, 1720
 - patient selection for, 453
 - percutaneous needle, of musculoskeletal masses, 2677
 - prostate
 - detailed mapping of disease foci in, 1800
 - postbrachytherapy, disease and treatment effects on, 1829
 - single microscopic focus on, postoperative outcome and, 1810
- Bipolar symptoms, interferon-alpha-2b and, 356
- Bisphosphonates, for skeletal complications, in breast cancer, 363
- Blacks
- bladder cancer in, stage at diagnosis of, 1349
 - breast cancer outcome in, 2202
- Bladder cancer
- chemoradiotherapy for, 1089
 - management and outcome in, in Canada, population-based study of, 142
 - p21, p53 and mdm2 in, prognosis and, 619
 - smoking and, 630
 - stage at diagnosis of, race and, 1349
- Blastoma, pleuropulmonary, management and prognosis of, 1396
- Blood tests, fecal occult, guaiac vs. immunochemical, sensitivity of, 46
- Body mass index, breast cancer risk and, 369
- Body weight, breast cancer risk and, 369
- Bone, myogenic tumors of, post-transplant, Epstein-Barr virus in, 467
- Bone disease, in metastatic breast cancer, predictors of, 363
- Bone marrow transplantation
- for chronic myeloid leukemia, in younger patients, 1647
 - for HIV-associated non-Hodgkin's lymphoma, 680
- Bone metastasis
- in metastatic breast cancer, predictors of, 363
 - in soft tissue sarcoma, routine scintigraphy for, 1726

- Bone resorption, in oral cancer, interleukin-6 enhancement of, 1966
- Bone scintigraphy, in soft tissue sarcoma staging, 1726
- Botulinum toxin, for Frey syndrome, 1659
- Brachytherapy. *See also* Radiation therapy
with intraluminal iridium-192, for biliary papillomatosis, 69
for prostate cancer, 135
effects of on biopsy results, 1829
prostatourethral-rectal fistula after, 2085
- Brain. *See also under* Cerebral
- Brain metastasis
from prostate cancer, 706 (letter)
from unknown primary, 1095
- Brain stem tumors, pathologic classification of, 1569
- Brain tumors
brain stem, pathologic classification of, 1569
glioblastoma multiforme, trofosfamide and etoposide for, 2131
glioma
carmustine resistance in, transforming growth factor- β 1-binding protein and, 850
venous thromboembolism in, 640
- BRCA1* heterozygotes, premalignant ovarian changes in, 383
- BRCA1* mutation, breast cancer and, in Asian women, 811
- BRCA2*, allelic imbalance at, in nonsmall cell lung cancer, 1933
- Breast
cystosarcoma phyllodes of, treatment of, 1502
fiberoptic ductoscopy of, 1512
tissue density of, cancer risk and, 369
- Breast cancer
advanced, doxorubicin and paclitaxel for, 2169
axillary tumor free nodes in, number of, prognosis and, 213 (letter)
biopsy in, percutaneous, imaging-histologic discordance in, 2538
BRCA1 mutation and, in Asian women, 811
CEA immunoscintigraphy for, 104
chemotherapy response in, apoptosis and cellular proliferation and, 2145
COX-2 in, 2637
cyclophosphamide-doxorubicin vs. cyclophosphamide-methotrexate-5-fluorouracil for, 2521
ductal in situ
HER-2/*neu* amplification and p53 mutation in, 2153
local recurrence of, outcome in and factors affecting, 2323 (letter)
estrogen receptor- α/β mRNA expression in, PCR analysis of, 1732
gastric metastasis in, presentation, endoscopic features and treatment of, 2214
hereditary prostate cancer and, 1315
hormone replacement therapy and, in benign breast disease, 20246
ICI 182,780 (Faslodex) for, 817
intratumoral injection of dendritic cells for, 2646
lobular, hormone replacement therapy and, 1867 (letter)
lymphatic mapping in, 236
lymph node metastasis in
computer simulations of, 2527
sentinel vs. nonsentinel node, 574
mortality in, in Appalachian women, 1593
node-negative, DNA content of, prognostic value of, 1748
pegylated liposomal doxorubicin (Doxil) for, 1037
persistent impact of on functional health status, 2176
postmastectomy irradiation for, axillary node extranodal soft tissue extension and, 223 (letter)
psychosocial group intervention for, in Japan, 1026
refractory, paclitaxel for, 2195
relaxin-like factor in, 2161
screening for
in Asian American and Pacific Islanders, 696
CEA immunoscintigraphy with, 104
as second primary, 1999
sentinel/completion lymphadenectomy for, 236
sentinel node biopsy in, false negative, after preoperative chemotherapy, 2187
serum CYFRA 21-1 in, 1285
skeletal complications in, predictors of, 363
survival in, in U.S. vs. Europe, 893
tamoxifen for, uterine cancer surveillance after, 800
treatment of
less than definitive, recurrence and mortality and, 1739
in older women, 561
weight, body mass index and tissue density and, 369
Breast conserving surgery, in older women, 561
Breast disease, benign
cancer risk with hormone replacement therapy and, 2046
relaxin-like factor in, 2161
Bronchoscopy, fluorescence, in lung cancer detection, 2468
Bryostatins-1, for metastatic renal cell carcinoma, 615
- C**
- Ca²⁺/calmodulin-dependent protein kinase IV, in hepatocellular carcinoma, 1910
- CA 19-9, in pancreatic cancer, vs. tissue polypeptide specific antigen, 83
- CA 125, in fallopian tube cancer, prognosis and, 1555
- Cadherins
in cervical cancer, 2053
in ulcerative colitis-associated colorectal cancer, 733
- Calcium channel blockers, cancer risk and mortality with, 165
- CaM-kinase IV, in hepatocellular carcinoma, 1910
- Canada
bladder cancer management and outcome in, population-based study of, 142
cancer incidence rates and socioeconomic status in, vs. in U.S., 901

- Cancer incidence
socioeconomic status and, in Canada vs. U.S., 901
in very elderly, in Netherlands, 1121
- Cancer of the Liver Italian Program (CLIP) score, 2266
- Cancer of unknown primary site, paclitaxel-carboplatin-etoposide for, 2655
- Cancer pain consultation, outcome of, 920
- Cancer patient, personal account of, 229
- Cancer risk, with calcium channel blockers, 165
- Cancer survival, in U.S. vs. Europe, 893
- Cancer treatment, compliance with, use of alternative therapies and, 873
- Carboplatin
for cancer of unknown primary site, 2655
for metastatic retinoblastoma, 2117
with radiotherapy
for head and neck cancer, 2099
for nonsmall cell lung cancer, 534
- Carcinoembryonic antigen, isolated elevation of, in colorectal cancer, radioimmunoguided surgery for, 1692
- Carcinoembryonic antigen immunoscintigraphy, for breast cancer, 104
- Carcinoembryonic antigen mRNA, in colorectal cancer, prognosis and, 970
- Carcinoids, multiple duodenal, 963
- Carmustine, resistance to, transforming growth factor- β 1-binding protein and, 850
- Carotid body paraganglioma, vs. schwannoma with angiosarcoma, 1577
- Cartilaginous tumors, connective tissue growth factor in, 1466
- Catalase, in prostatic intraepithelial neoplasia and cancer, 123
- Catenin, in ulcerative colitis-associated colorectal cancer, 733
- Cathepsin B
in chondrosarcoma, 995
in lymph nodes, in nonsmall lung cancer, prognosis and, 2282
- Cathepsins, in early stage gastric cancer, 482
- CD44
in non-Hodgkin's lymphoma and chronic lymphocytic leukemia, during interferon therapy, 1474
in ulcerative colitis-associated colorectal cancer, 733
- Cell adhesion molecules
in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia, during interferon therapy, 1474
in ulcerative colitis-associated colorectal cancer, 733
- Cellular proteases, in chondrosarcoma, 995
- Central Europe, melanoma in, time trends of, 1269
- Central nervous system involvement, in cutaneous B-cell lymphoma, 913
- Central neurocytoma, 1111
- c-erbB-3, in verrucous oral cancer, 2597
- Cerebral lymphoma, radiation therapy with/without chemotherapy for, 1359
- Cerebral metastasis
from prostate cancer, 706 (letter)
from unknown primary, 1095
- Cervical cancer
cadherins in, 2053
early invasive adenocarcinoma, histopathology of, 1048
in Ivory Coast, 653
mortality in, in Appalachian women, 1593
non-squamous cell, increasing incidence of, in Norway, 1291
radiotherapy for, high growth fraction at 9 Gy in, prognosis and, 1526
screening for
in Asian American and Pacific Islanders, 696
direct visual inspection vs. Pap smear for, 826
in resource-poor settings, 826
squamous cell, p53 and p21 in, 1300
survival in, in U.S. vs. Europe, 893
- Cervical dysplasia, folate, homocysteine, vitamin B₁₂ and cysteine as markers for, 376
- Cervix, direct visual inspection of, vs. Pap smear, 826
- c-ets1, in endometrial cancer, 2059
- Chemoembolization
hepatic arterial
with percutaneous microwave coagulation therapy, 1245
preoperative, in hepatocellular carcinoma, 2606
for pancreatic cancer, 303
- Chemoradiotherapy. *See also* Chemotherapy; Radiation therapy
for bladder cancer, 1089
for cerebral lymphoma, 1359
for esophageal cancer, 946, 2144 (erratum)
for extrahepatic biliary tract recurrence of gastric cancer, 29
for head and neck cancer, 2099
for nonsmall cell lung cancer, 534
for oral/oropharyngeal cancer, 939
for pancreatic cancer, vs. resection, as initial therapy, 314
for pediatric nasopharyngeal cancer, 690
for retinoblastoma, with metastasis, 2117
- Chemosensitivity testing, for hepatic arterial infusion chemotherapy, 288
- Chemotherapy. *See also specific drugs*
arterial infusion, for pancreatic cancer, 303
for breast cancer, 817, 1037
in advanced disease, 2169
in older women, 561
in refractory disease, 2195
response to, apoptosis and cellular proliferation and, 2145
for cancer of unknown primary site, 2655
for colorectal cancer, 1699
for fallopian tube cancer, 2076
for glioblastoma multiforme, 2131
for gynecologic cancer, quality of life and, 1402
for head and neck cancer, 2587

- hepatic arterial infusion, thymidylate synthase quantitation and in vitro chemosensitivity testing for, 288
 for hepatoblastoma presenting with lung metastasis, 1845
 for hepatocellular carcinoma, 750
 for hepatoma, 983
 for lung cancer, 89, 516, 543, 750, 763, 769, 774, 1714
 in elderly, 328, 1953
 in induction therapy, 1946
 in metastatic disease, 2622
 p53 mutations and, 769
 with radiotherapy, 534
 for maxillary sinus cancer, 1925
 for melanoma, with interferon- α , 2630
 nausea and vomiting in, ganisetron vs. ondansetron for, 2301
 for neuroblastoma, with granulocyte-colony stimulating factor, 2122
 for osteosarcoma, reproductive function after, 1961
 for ovarian cancer, in Stage III/IV disease, 1547
 for pancreatic cancer, 1706
 patient's experience of, 229
 for peritoneal mesothelioma, 1279
 pharmacokinetic modulating, for hepatic colorectal metastasis, 1228
 preoperative, for oral/oropharyngeal cancer, with concurrent chemoradiotherapy, 939
 for prostate cancer, 1824
 in weekly 1-hour infusion, 431, 1412 (erratum)
 with radiotherapy. *See* Chemoradiotherapy
 reduced efficacy of, after pneumoperitoneum, 262
 for retinoblastoma, with metastasis, 2117
 for soft tissue sarcoma, 177
- Chest radiography
 in lung cancer screening. *See* Lung cancer, screening for
 radiation exposure in, 2457
- Children. *See also specific cancers*
 glioblastoma multiforme in, trofosfamide and etoposide for, 2131
 leukemia in. *See* Leukemia
 lymphoma in, pesticide exposure and, 2315
 metastatic retinoblastoma in, chemoradiotherapy for, 2117
 nasopharyngeal cancer in, chemoradiotherapy for, 680
 neuroblastoma in, granulocyte-colony stimulating factor with chemotherapy for, 2122
 salivary gland tumors in, Epstein-Barr virus in, 463
- Chinese. *See also* Asians
 Chinese staging system, for nasopharyngeal cancer, vs. UICC system, 242
- Chondroma, connective tissue growth factor in, 1466
- Chondrosarcoma
 cathepsin B in, 995
 connective tissue growth factor in, 1466
 urokinase plasminogen activator in, 995
- CHOP regimen, for cerebral lymphoma, with radiation therapy, 1359
- Choriocarcinoma, cyclin E in, 673
- Chromosome 3p23, loss of heterozygosity at, in colorectal cancer, prognosis and, 1220
- Chronic duodenitis, multiple carcinoids and endocrine cell micronests in, 963
- Chronic hepatitis C
 hepatocellular carcinoma and, incidence-related factors in, 53
 transforming growth factor- α mRNA in, 977
- Chronic leukemia. *See* Leukemia
- Chronic lymphoproliferative disorders, B-cell, T-cell proliferation in, B7 molecules and, 1259
- Cigarette smoking. *See* Smoking
- Cisplatin
 for esophageal cancer, with radiation therapy, 946
 for hepatoblastoma presenting with lung metastasis, 1845
 for lung cancer
 in elderly, 1953
 with gemcitabine, 1714
 in induction therapy, 1946
 in metastatic disease, 2622
 with paclitaxel and ifosfamide, 774
 for melanoma, with interferon- α , 2630
 for metastatic retinoblastoma, 2117
 for neuroblastoma, with granulocyte-colony stimulating factor, 2122
 for ovarian cancer, 1547
 for pancreatic cancer, arterial infusion of, 303
 for peritoneal mesothelioma, 1279
 for soft tissue sarcoma, 177
- CLIP score, 2266
- c-MYC, in nodular melanoma, 97
- Colorectal cancer
 carcinoembryonic antigen mRNA in, prognosis and, 970
 classification of by tumor edge morphology, 1901
 COX-2 in, 2637
 familial, Swedish cohort study of, 741
 5-fluorouracil for, small intestinal toxicity of, 711 (letter)
 guaiac vs. immunochemical occult blood test for, sensitivity of, 46
 hepatic metastasis in
 blood flow in, 1236
 distribution of, 285
 fibrous pseudocapsule of, 257
 microwave coagulation therapy for, 276
 pharmacokinetic modulating chemotherapy for, 1228
 tumor thickness and, 35
 vascular endothelial growth factor and, 488
 with high-frequency microsatellite instability, clinicopathology of, 2025
 loss of heterozygosity at 3p23 in, prognosis and, 1220
 metastatic, 9-aminocamptothecin for, 1699

- offspring of women with, lymphoma risk in, 741
 - paclitaxel radiosensitizing effect in, p53 and, 1893
 - radioimmunoguided surgery for, 1692
 - recurrent, with isolated CEA elevation, radioimmunoguided surgery for, 1692
 - survival in, in U.S. vs. Europe, 893
 - tumor thickness in, prognosis and, 35
 - ulcerative colitis-associated, cell adhesion molecules in, 733
 - Community income, cancer incidence and, in Canada vs. U.S., 901
 - Complementary medicine, compliance with standard treatment and, 873
 - Compliance, with standard treatment, use of alternative therapies and, 873
 - Computed tomography
 - in Hodgkin's disease, correlation of with lymphangiography and Ga-67 SPECT, 1371
 - in lung cancer screening, 2457, 2474. *See also* Lung cancer, screening for
 - in Japan, 2485
 - radiation exposure in, 2457
 - in ovarian cancer, in surgical outcome prediction, 1532
 - in pancreatic cancer, cost analysis for, 1917
 - Computer simulations, of lymph node metastasis, in breast cancer, 2527
 - Congenital sacrococcygeal teratoma, DNA ploidy in, 932
 - Connective tissue growth factor, in cartilaginous tumors, 1466
 - Consultation, cancer pain, outcome of, 920
 - Counseling, for breast cancer patients, in Japan, 1026
 - COX-2
 - in prostate cancer, 589
 - in pulmonary, colonic and mammary tumors, 2637
 - Cutaneous B-cell lymphoma
 - anti-CD20 antibody for, 1835
 - central nervous system involvement in, 913
 - Cutaneous lymphoma, interferon- α for, 1603
 - Cy5.5 complex, in immunofluorescent tumor localization, 1134
 - Cyclin-dependent kinases, in gastric cancer, prognosis and, 2247
 - Cyclin E, in gestational trophoblastic disease, 673
 - Cyclooxygenase-2
 - in prostate cancer, 589
 - in pulmonary, colonic and mammary tumors, 2637
 - Cyclophosphamide
 - for breast cancer
 - with doxorubicin, 2521
 - with methotrexate and 5-fluorouracil, 2521
 - for cerebral lymphoma, with radiation therapy, 1359
 - for metastatic retinoblastoma, 2117
 - for neuroblastoma, with granulocyte-colony stimulating factor, 2122
 - CYFRA 21-1
 - in breast cancer, 1285
 - in esophageal cancer, 1413
 - Cystectomy, for bladder cancer, population-based study of, 142
 - Cysteine, as cervical dysplasia marker, 376
 - Cysteine proteases, in early stage gastric cancer, 482
 - Cystosarcoma phyllodes of breast, treatment of, 1502
 - Czechoslovakia, lung cancer screening in, 2363
- D**
- D13S171*, allelic imbalance at, in nonsmall cell lung cancer, 1933
 - Dacarbazine, with interferon- α , for melanoma, 2630
 - Deep vein thrombosis, gliomas and, 640
 - Deleted colon carcinoma, in ulcerative colitis-associated colorectal cancer, 733
 - Delirium, in advanced cancer, prognostic impact of, 1145
 - Dendritic cells, intratumoral injection of, 2646
 - Dendritic cell sarcoma, of neck, 664
 - Depression
 - interferon-alpha-2b and, 356
 - after successfully treated lung cancer, 1172
 - Developing countries. *See also specific countries*
 - cost-effective early detection programs in, 475
 - Dexamethasone, low-dose oral, for prostate cancer, 2570
 - Diet
 - as cervical dysplasia marker, 376
 - gastric cancer survival and, 1205
 - DNA content
 - of breast cancer, prognostic value of, 1748
 - of colorectal cancer, with high-frequency microsatellite instability, 2025
 - of congenital sacrococcygeal teratoma, 932
 - of gastric lymphoma, 12
 - of renal cell carcinoma, p53 and *bcl-2* and, 1065
 - Docetaxel
 - for hepatoma, 983
 - lymphopenia and, 1380
 - for nonsmall cell lung cancer, 516
 - weekly administration of, in elderly, 328
 - with paclitaxel, weekly administration of, 2309
 - Doxil, for breast cancer, 1037
 - Doxorubicin
 - for breast cancer, 2169
 - with cyclophosphamide, 2521
 - pegylated liposomal, 1037
 - for cerebral lymphoma, with radiation therapy, 1359
 - for hepatoblastoma presenting with lung metastasis, 1845
 - for neuroblastoma, with granulocyte-colony stimulating factor, 2122
 - for peritoneal mesothelioma, 1279
 - Ductal carcinoma in situ. *See also* Breast cancer
 - HER-2/*neu* amplification and p53 mutation in, 2153
 - local recurrence of, outcome in and factors affecting, 2323 (letter)
 - Ductoscopy, fiberoptic, for nipple discharge, 1512
 - Duodenal carcinoids, endocrine cell micronests and, 963
 - Duodenitis, chronic, multiple carcinoids and endocrine cell micronests in, 963

E

- Early Lung Cancer Action Project, 2474
- E-cadherin, in ulcerative colitis-associated colorectal cancer, 733
- Elderly
 age limits for, in non-Hodgkin's lymphoma, 2667
 breast cancer in, treatment of, 561
 cancer incidence in, in Netherlands, 1121
 nonsmall cell lung cancer in, chemotherapy for, 328, 1953
- Embolization
 hepatic arterial
 with percutaneous microwave coagulation therapy, 1245
 preoperative, 2606
 transcatheter arterial, with arterial infusion chemotherapy, for pancreatic cancer, 303
- Emotional status
 of breast cancer patients
 in Japan, 1026
 persistent changes in, 2176
 depression after successfully treated lung cancer, 1172
 in gynecologic cancer, with extensive chemotherapy, 1402
 personal account of, 229
 in prostate cancer, before/after radiation therapy, 1322
 in successfully treated lung cancer, 1172
- Enchondroma, connective tissue growth factor in, 1466
- Endocrine cell micronests, in chronic duodenitis, 963
- Endometrial cancer
 c-ets1 in, 2059
 microsatellite instability in
 analysis at 10q25-q26 and, 1773
 clinical significance of, 1758
 surveillance for, in tamoxifen-treated breast cancer survivors, 800
 survival in, in U.S. vs. Europe, 893
 tissue sampling in, diagnostic yield of, 1765
- Endometrial sampling, diagnostic yield of, 1765
- Endostatin, in antiangiogenic gene therapy, 1181
- Enzymes, antioxidant, in prostatic intraepithelial neoplasia and cancer, 123
- Epidermal growth factor, salivary, mucositis and, in oropharyngeal radiation therapy, 2258
- Epirubicin
 for nonsmall cell lung cancer, 89
 for ovarian cancer, 1547
- Eppendorf pO₂ measurements, in prostate cancer, stage and patient age and, 2018
- Epstein-Barr virus
 in pediatric salivary gland tumors, 463
 in post-transplant myogenic tumors of bone, 467
- ERBB-2 in ovarian tissue, in *BRCA1* heterozygotes, 383
- Errata, 473, 1412, 2144
- Esophageal cancer
 adenocarcinoma, lymph node micrometastasis and tumor cell microinvolvement in, 1874
 CYFRA 21-1 in, 1413
 fragile histidine triad gene in, 5
 initial lymph node metastasis in, localization of, 1869
 invasiveness of, *Ets-1* and, 1670
 serum p53 antibody in, 1677
 squamous cell
 KAI1/CD82 in, 955
 neoadjuvant chemoradiotherapy for, 946, 2144 (erratum)
 superficial, ductal involvement in, 248
- Esophagogastric junction adenocarcinoma, lymph node micrometastasis and tumor cell microinvolvement in, 1874
- Estramustine, for prostate cancer, 1824
- Estrogen receptor- α/β mRNA expression, in breast cancer, PCR analysis of, 1732
- Estrogen replacement therapy
 in benign breast disease, cancer risk and, 2046
 lobular breast cancer and, 1867 (letter)
- Etoposide
 for cancer of unknown primary site, 2655
 for glioblastoma multiforme, 2131
 for metastatic retinoblastoma, 2117
 for neuroblastoma, with granulocyte-colony stimulating factor, 2122
 for nonsmall cell lung cancer
 in elderly, 1953
 in induction therapy, 1946
 with oral administration, 543
 for soft tissue sarcoma, 177
- Ets-1*
 in esophageal cancer, tumor invasiveness and, 1670
 in meningioma, 2292
- Europe. *See also specific countries*
 cancer survival in, vs. in U.S., 893
- Ewing's sarcoma
 INK4A deletion in, prognosis and, 783
 p53 in, prognosis and, 783
- Extrahepatic bile ducts, noninvasive/minimally invasive papillary carcinoma of, 508
- Extremity osteosarcoma, chemotherapy for, reproductive function after, 1961

F

- Fallopian tube cancer
 CA 125 in, prognosis and, 1555
 treatment and prognosis in, 2076
- Familial medullary thyroid carcinoma syndrome, RET mutation carriers of, thyroidectomy for, 863
- Familial prostate cancer, breast and gastric cancer and, 1315
- Fas ligand, circulating soluble, in gastric cancer, 2560
- Faslodex, for breast cancer, 817
- Fatigue, in prostate cancer, before/after radiation therapy, 1322
- FDG positron emission tomography, in melanoma, 1019
- Fecal occult blood tests, guaiac vs. immunochemical, sensitivity of, 46

Femoral head, avascular necrosis of, in interferon-treated chronic myeloid leukemia, 1482

Fertility

after chemotherapy, for osteosarcoma, 1961
preservation of, for ovarian germ cell tumors, 391

¹⁸F-fluoro-2-deoxy-D-glucose PET, delayed, in pancreatic cancer, 2547

FHIT, in esophageal cancer, 5

Fiberoptic ductoscopy, for nipple discharge, 1512

Fibrillary astrocytoma, pathologic classification of, 1569

Fistula, prostaticourethral-rectal, after brachytherapy, 2085

Flow cytometry

in breast cancer, prognostic value of, 1748

in colorectal cancer, with high-frequency microsatellite instability, 2025

in congenital sacrococcygeal teratoma, 932

in gastric lymphoma, 12

in renal cell carcinoma, p53 and *bcl-2* and, 1065

Fluconazole, oral, for fungal infection prophylaxis, 1611

Fluorescence bronchoscopy, in lung cancer detection, 2468

2-Fluorine-18, 2-fluoro-2-deoxy-D-glucose PET scanning, in melanoma, 1019

5-Fluorouracil

for breast cancer, with cyclophosphamide and methotrexate, 2521

for esophageal cancer, with radiotherapy, 946

for head and neck cancer, with radiotherapy, 939

hepatic arterial infusion of, thymidylate synthase quantitation and in vitro chemosensitivity testing for, 288

for hepatic colorectal metastasis, 1228

for pancreatic cancer, via arterial infusion, 303

for renal cell carcinoma, with interleukin-2 and subcutaneous interferon- α , 597

small intestinal toxicity of, 711 (letter)

Folate, as cervical dysplasia marker, 376

Follicular dendritic cell sarcoma, of neck, 664

Foregut carcinoids, duodenal, 963

Fotemustine, with interferon- α , for melanoma, 2630

Fractures, pathologic, in breast cancer, predictors of, 363

Fragile histidine triad gene, in esophageal cancer, 5

France, gallbladder cancer incidence trends and management in, 757

Frey syndrome, botulinum toxin for, 1659

Frozen section analysis, of sentinel nodes, in melanoma, 1720

Functional health status

in breast cancer, persistent changes in, 2176

symptom distress and, 1634

Fungal infections, neutropenic, oral fluconazole prophylaxis for, 1611

G

Gabapentin, for interferon-alpha-2b-associated mood instability, 356

Gallbladder cancer, incidence trends and management of, in France, 757

Gallium-67 SPECT, in Hodgkin's disease, correlation of with lymphangiography and CT, 1371

Ganglioneuroblastoma, nodular, prognostic classification of, 1150

Ganisetron, for chemotherapy-induced nausea and vomiting, 2301

Gastrectomy

early and late recurrence after, 255

with prophylactic radical lymphadenectomy, 1425

Gastric cancer

in Asian patients in U.S., clinical features and survival in, 1183

biliary obstruction in, chemoradiation for, 29

circulating soluble Fas ligand in, 2560

differentiated type early, gastric type mucin expression in, 724

early stage, cathepsins in, 482

hereditary prostate cancer and, 1315

in Japan vs. U.S., 2237, 2555

p27^{Kip1} in, prognosis and, 1684, 2247

P-glycoprotein in, p53 and, 21

prophylactic radical lymphadenectomy with gastrectomy for, 1425

surgery for. *See* Gastrectomy

survival in

premorbid diet and, 1205

in U.S. vs. Europe, 893

well vs. poorly differentiated, pathology and prognosis of, 1418

Gastric lymphoma

DNA content of, 12

soluble intercellular adhesion molecules-1 in, prognosis and, 1387

in Turkey, 12

Gastric metastasis, in breast cancer, presentation, endoscopic features and treatment of, 2214

Gastric type mucin expression, in differentiated type early gastric carcinoma, 724

Gemcitabine

for hepatocellular carcinoma, 750

for lung cancer, 516, 543

with cisplatin, 1714

with etoposide, 543

in metastatic disease, 2622

with vinorelbine, 763

for pancreatic cancer, with leucovorin-modulated UFT, 1706

Gene therapy

antiangiogenic, 1181

for prostate cancer, 1329

Germany

lung cancer histopathology in uranium workers in, 2613

lung cancer screening in, cost-effectiveness of, 2489

thyroid cancer in, 1

patterns of care for, 192

Germ cell tumors, ovarian, conservative surgery for, 391

Gestational trophoblastic disease, cyclin E in, 673

- Gleason grading, of prostate cancer, Web-based tutorial for, 1818
- Glioblastoma multiforme, trofosfamide and etoposide for, 2131
- Glioma
- carmustine resistance in, transforming growth factor- β 1-binding protein and, 850
 - venous thromboembolism in, 640
- Glutathione, in pancreatic cancer, 1440
- Glyceraldehyde-3-phosphate dehydrogenase, in renal cell carcinoma, 152
- Grading, of prostate cancer, Web-based tutorial for, 1818
- Granulocyte-colony stimulating factor
- for neuroblastoma, 2122
 - for nonsmall cell lung cancer, 516
- Group therapy, for breast cancer patients, in Japan, 1026
- Gustatory sweating, botulinum toxin for, 1659
- Gynecologic cancer. *See also specific types*
- chemotherapy for, quality of life and, 1402

H

- Head and neck cancer
- bone invasion in, interleukin-6 enhancement of, 1966
 - carboplatin with radiation therapy for, 2099
 - induction paclitaxel for, 2587
 - preoperative chemotherapy followed by chemoradiotherapy for, 939
 - radiation therapy for, mucositis in, salivary epidermal growth factor and, 2258
 - survival in, in India, 437
- Head and neck sarcoma, prognostic factors in, 868
- Health insurance, breast cancer outcome and, 2202
- Health maintenance organizations, breast cancer outcome and, 2202
- Healthy People 2000, breast and cervical cancer screening in Asian American and Pacific Islanders and, 696
- Helicobacter* spp., hepatocellular carcinoma and, 1431
- Heparin, post-pneumoperitoneum survival time and, 262
- Hepatic arterial chemoembolization
- with percutaneous microwave coagulation therapy, 1245
 - preoperative, in hepatocellular carcinoma, 2606
- Hepatic arterial infusion chemotherapy, thymidylate synthase quantitation and in vitro chemosensitivity testing for, 288
- Hepatic failure, raltitrexed and, 890
- Hepatic metastasis, in colorectal cancer
- blood flow in, 1236
 - distribution of, 285
 - fibrous pseudocapsule of, 257
 - microwave coagulation therapy for, 276
 - pharmacokinetic modulating chemotherapy for, 1228
 - tumor thickness and, 35
 - vascular endothelial growth factor and, 488
- Hepatic resection, outcome of, *HFE* mutations and, 297
- Hepatitis B, hepatocellular carcinoma and, in India, 2322 (letter)
- Hepatitis C
- hepatocellular carcinoma and, incidence-related factors in, 53
 - transforming growth factor- α mRNA in, 977
- Hepatoblastoma, presenting with lung metastases, 1845
- Hepatocellular carcinoma
- Ca^{2+} /calmodulin-dependent protein kinase IV in, 1910
 - in chronic hepatitis C, incidence-related factors in, 53
 - early vs. late recurrence of, risk and prognostic factors for, 500
 - gemcitabine for, 750
 - Helicobacter* spp. and, 1431
 - hepatic arterial chemoembolization for
 - with percutaneous microwave coagulation therapy, 1245
 - preoperative, 2606 - hepatic arterial infusion chemotherapy for, thymidylate synthase quantitation and in vitro chemosensitivity testing for, 288
 - HFE* mutations in, surgical outcome and, 297
 - nuclear factor κB in, 2266
 - p16 inactivation in, 60
 - p53 in, in India, 2322 (letter)
 - staging of, 2266
 - transforming growth factor- α mRNA in, 977
- Hepatoma
- hepatic arterial infusion chemotherapy for, thymidylate synthase quantitation and in vitro chemosensitivity testing for, 288
 - 2-methoxyestradiol vs. docetaxel vs. paclitaxel for, 983
- HER-2/*neu*, in ductal carcinoma in situ, 2153
- Hereditary medullary thyroid carcinoma syndrome, RET mutation carriers of, thyroidectomy for, 863
- Hereditary prostate cancer, breast and gastric cancer and, 1315
- Heterogeneous nuclear ribonucleoprotein A2/B1, in lung cancer screening, 2465
- HFE* mutations, in hepatocellular carcinoma, surgical outcome and, 297
- Hip, osteonecrosis of, in interferon-treated chronic myeloid leukemia, 1482
- HIV infection, non-Hodgkin's lymphoma in, stem cell transplant for, 680
- HMOs, breast cancer outcome and, 2202
- Hodgkin's disease. *See also Lymphoma*
- correlation of Ga-67, SPECT, CT and lymphangiography in, 1371
 - epidemiology of, in Southern Taiwan, 1586
 - image-guided core-needle biopsy in, 647
 - survival in, in U.S. vs. Europe, 893
- Homocysteine, as cervical dysplasia marker, 376
- Hormone receptor status
- in breast cancer, PCR analysis of, 1732
 - in ovarian cancer, prognosis and, 1783
- Hormone replacement therapy
- in benign breast disease, cancer risk and, 2046
 - lobular breast cancer and, 1867 (letter)
- Hospice care, morphine in, 220 (letter)

- Human immunodeficiency virus infection, non-Hodgkin's lymphoma in, stem cell transplant for, 680
- Human pancreatic ribonuclease 1, in pancreatic cancer, 1252
- Human papillomavirus DNA testing, vs. Pap smear, 826
- Human papillomavirus infection, cervical cancer and, basal cell tetrasomy and p53/p21 expression and, 1300
- Human tumor colony-forming assay, for hepatic arterial infusion chemotherapy, 288
- Hydatidiform mole, cyclin E in, 673
- Hypercalcemia, in breast cancer, predictors of, 363
- Hyper eosinophilic syndrome, lymphomatoid papulosis and, 2138
- Hypergastrinemia, duodenal carcinoids and, 963
- Hyperthermia
 - for peritoneal mesothelioma, 1279
 - with radiation therapy, for prostate cancer, 399
- Hypomethylation, in acute lymphoblastic leukemia-associated leukoencephalopathy, 925
- Hypopharyngeal cancer. *See also* Head and neck cancer survival in, in India, 437
- Hypoxia, in prostate tumors, stage and patient age and, 2018
- Hysterectomy, pelvic nerve plexus trauma during, 834, 2144 (erratum)

I

- ICI 182,780, for breast cancer, 817
- Ifosfamide
 - for nonsmall cell lung cancer, with paclitaxel and cisplatin, 774
 - for soft tissue sarcoma, 177
- Image-guided core-needle biopsy, in lymphoma, 647
- IMC-C225, inhibition of pancreatic tumor growth by, 74
- Immune surveillance, metastatic susceptibility and, 1626
- Immunofluorescence, in tumor localization, using single chain Fv fragment of monoclonal antibody, 1134
- Immunoscintigraphy, carcinoembryonic antigen, for breast cancer, 104
- Immunosuppression, post-transplant, Epstein-Barr virus-associated myogenic tumors of bone and, 467
- Immunotherapy. *See also specific agents and modalities* intratumoral injection of dendritic cells in, 2646
 - for prostate cancer, 1329
- Incidence rates, socioeconomic status and, in Canada vs. U.S., 901
- India
 - head and neck cancer survival in, 437
 - hepatocellular carcinoma in, p53 in, 2322 (letter)
- Infertility
 - after chemotherapy, for osteosarcoma, 1961
 - prevention of, in ovarian germ cell tumors, 391
- Inguinal lymphadenectomy, saphenous vein preservation in, in vulvar cancer, 1520
- INK4A deletion, in Ewing's sarcoma, prognosis and, 783

- Institute of Medical Informatics, patterns of care for thyroid cancer in Germany, 192
- Insulin-like molecule 3, in normal vs. neoplastic breast tissue, 2161
- Insurance, breast cancer outcome and, 2202
- Intercellular adhesion molecule-1, in non-Hodgkin's lymphoma and chronic lymphocytic leukemia, during interferon therapy, 1474
- Interferon- α
 - for chronic myeloid leukemia
 - avascular necrosis of femoral head and, 1482
 - in younger patients, 1647
 - for lymphomatoid papulosis, 1603
 - for melanoma
 - with cisplatin-dacarbazine-fomustine, 2630
 - in recurrence, 1498
 - for metastatic osteosarcoma, with retinoic acid, 2661
 - for renal cell carcinoma
 - with 5-fluorouracil and interleukin-2, 597
 - with infusional interleukin-2 and 5-fluorouracil, 597
- Interferon-alpha-2b, for melanoma, mania and bipolar syndromes and, 356
- Interleukin-2, plus 5-fluorouracil and subcutaneous interferon- α , for renal cell carcinoma, 597
- Interleukin-6, in oral cancer, enhanced bone invasion and, 1966
- International Association for the Study of Lung Cancer Worldwide Educational Program on Lung Cancer, 2331
- International Prognostic Index, for non-Hodgkin's lymphoma, age classification and, 2667
- International Union Against Cancer
 - staging system of, for nasopharyngeal cancer, 242
- Telepathology Consultation Center, 187
- Internet-based tutorial, for prostate cancer grading, 1818
- Intestinal toxicity, of 5-fluorouracil, 711 (letter)
- Iridium-192, intraluminal, for biliary papillomatosis, 69
- Italy, lung cancer in, screening for, in smokers, 2345
- Ivory Coast, cancer incidence in, 653

J

- Japan. *See also* Asians
 - gastric cancer in, vs. in U.S., 2237, 2555
 - lung cancer screening in, 2392
 - computed tomography in, 2485
 - cost-effectiveness of, 2489
 - psychosocial group intervention for breast cancer patients in, 1026

K

- KAI1/CD82, in esophageal squamous cell carcinoma, 955
- Kaposi sarcoma, in Ivory Coast, 653
- κ B, in hepatocellular carcinoma, 2266
- Ki-67
 - in breast cancer
 - chemotherapy response and, 2145
 - prognosis and, 1748
 - in Ewing's sarcoma, prognosis and, 783

- in nonsmall cell lung cancer, postoperative survival and, 1457
 - Koreans. *See also* Asians
 - nasal-type natural killer/T-cell and natural killer precursor lymphoma in, 2106
 - K-ras, in polypoid vs. nonpolypoid colorectal cancer, 1901
- L**
- Laparoscopic surgery, pneumoperitoneum for, tumor cell growth and chemotherapy efficacy after, 262
 - Large B-cell lymphoma of legs, anti-CD20 antibody for, 1835
 - Large cell lymphoma, angiotrophic, superior vena cava syndrome and, 2515
 - Large T-cell lymphoma, lymphomatoid papulosis and, 2138
 - Laryngeal cancer. *See also* Head and neck cancer
 - squamous cell, ascorbic acid accumulation in, 171
 - survival in, in India, 437
 - Latent membrane protein 1, in nasopharyngeal cancer, metastasis and, 715
 - Latent transforming growth factor- β 1-binding protein, carmustine resistance and, 850
 - Leucovorin-modulated UFT, with gemcitabine, for pancreatic cancer, 1706
 - Leukemia
 - acute lymphoblastic, leukoencephalopathy in, hypomethylation and, 925
 - acute myelogenous
 - p16/p14 locus deletion and MDM-2 expression in, prognosis and, 1976
 - after strontium-89 for prostate cancer, 226 (letter)
 - B-cell chronic lymphocytic, CD44 and intercellular adhesion molecule-1 in, during interferon therapy, 1474
 - chronic myeloid
 - BCR/ABL negative, neutrophil hyperfunction in, 561
 - erythroid differentiation in, proline-directed protein kinase F_A and, 1004
 - interferon-treated, avascular necrosis of femoral head and, 1482
 - stem cell transplant and interferon- α for, in younger patients, 1647
 - Leukoencephalopathy, in acute lymphoblastic leukemia, hypomethylation and, 925
 - Leydig-insulin-like factor, in normal vs. neoplastic breast tissue, 2161
 - Lip, cancer of. *See also* Head and neck cancer
 - survival in, in India, 437
 - Liver. *See also under* Hepatic
 - Liver cancer. *See* Hepatocellular carcinoma; Hepatoma
 - Liver failure, raltitrexed and, 890
 - Liver metastasis, in colorectal cancer
 - blood flow in, 1236
 - distribution of, 285
 - fibrous pseudocapsule of, 257
 - microwave coagulation therapy for, 276
 - pharmacokinetic modulating chemotherapy for, 1228
 - tumor thickness and, 35
 - vascular endothelial growth factor and, 488
 - Lobular breast cancer, hormone replacement therapy and, 1867 (letter)
 - Lung cancer
 - Alliance for Lung Cancer Advocacy, Support, and Education (ALCASE) for, 2510
 - COX-2 in, 2637
 - early, extent of surgery in, survival and, 2432
 - early diagnosis of, survival and, 2387
 - histopathology of, in German uranium workers, 2613
 - immune response in, prognosis and, 2038
 - International Association for the Study of Lung Cancer Worldwide Educational Program on, 2331
 - macrophage migration inhibitory factor in, prognosis and, 334
 - nonsmall cell
 - allelic imbalance at *D13S171* and *p53* alterations in, 1933
 - carboplatin/paclitaxel with radiotherapy for, 534
 - cathepsin B in lymph nodes in, prognosis and, 2282
 - early stage central and peripheral, surgery for, 2438
 - gemcitabine for
 - with cisplatin, 1714
 - with docetaxel and granulocyte-colony stimulating factor, 516
 - with etoposide, 543
 - with paclitaxel and cisplatin, 2622
 - with vinorelbine, 763
 - Ki-67 in, postoperative survival and, 1457
 - multimodality therapy for
 - in elderly, 1953
 - induction, 1946
 - paclitaxel for
 - with epirubicin, 89
 - with gemcitabine and cisplatin, 2622
 - with ifosfamide and cisplatin, 775
 - p53* mutations and, 769
 - occult squamous cell
 - management of, 2445
 - treatment of, 2445
 - photodynamic therapy for, 2445
 - prevention of, 2377
 - in former smokers, 2505
 - screening for, 2334
 - bias in, 2369
 - computed tomography in, in Japan, 2485
 - cost-effectiveness of, 2502
 - in Germany, 2494
 - in Japan, 2489
 - in Czechoslovakia, 2363
 - Early Lung Cancer Action Project for, 2474
 - fluorescence bronchoscopy in, 2468
 - in Italy, 2345
 - in Japan, 2392, 2485, 2489
 - Mayo Lung Project for, 2352
 - molecular methods in, 2465

NCI cooperative program for, 2349
 NCI New York study of, 2356
 overdiagnosis in, 2369, 2422, 2432
 randomized trials of, 2397, 2399, 2422, 2449
 sensitivity and specificity in, 2453
 sputum cytology in, 2461
 survival and, 2369, 2387, 2422
 secretory leukoprotease inhibitor in, 1448
 small cell, prognostic factors for, 523
 successful treatment of, depression after, 1172
 survival in, in U.S. vs. Europe, 893
 videothoroscopic surgery vs. open resection for, 2497
 weekly docetaxel for, in elderly, 328
 Lung metastasis, hepatoblastoma presenting with, 1845
 Lymphadenectomy
 inguinal, saphenous vein preservation in, in vulvar cancer, 1520
 prophylactic radical, with gastrectomy, 1425
 selective, in melanoma, patient selection for, 453
 sentinel, indications and technique for, 236
 sentinel/completion, for skin cancer, 236
 Lymphangiography, in Hodgkin's disease, correlation of with Ga-67 SPECT and CT, 1371
 Lymphatic mapping, in skin cancer, 236
 Lymph node, cathepsin B in, in nonsmall lung cancer, prognosis and, 2282
 Lymph node biopsy
 image-guided core-needle, in Hodgkin's disease, 647
 sentinel node
 in breast cancer, false negative, after preoperative chemotherapy, 2187
 in melanoma
 frozen section analysis of, 1720
 patient selection for, 453
 Lymph node dissection. *See* Lymphadenectomy
 Lymph node metastasis
 in breast cancer
 axillary extranodal soft tissue extension of, 223 (letter)
 computer simulations, 2527
 in sentinel vs. nonsentinel nodes, 574
 from colorectal cancer, tumor thickness and, 35
 in esophageal cancer
 KAI1/CD82 and, 955
 localization of, 1869
 in esophagogastric junction adenocarcinoma, 1874
 in gastric cancer, in Japan vs. U.S., 2237
 in nasopharyngeal cancer, latent membrane protein 1 and matrix metalloproteinase 9 and, 715
 Lymphoma
 age limits for elderly patients in, 2667
 angiogenic large cell, superior vena cava syndrome and, 2515
 B-cell, telomerase activity in, 445
 CD44 and intercellular adhesion molecule-1 in, during interferon therapy, 1474
 in children, pesticide exposure and, 2315
 cutaneous, interferon- α for, 1603

cutaneous B-cell
 anti-CD20 antibody for, 1835
 central nervous system involvement in, 913
 epidemiology of, in Southern Taiwan, 1586
 gastric
 DNA content of, 12
 soluble intercellular adhesion molecules-1 in, prognosis and, 1387
 in Turkey, 12
 HIV-associated, stem cell transplant for, 680
 Hodgkin's. *See* Hodgkin's disease
 image-guided core-needle biopsy in, 647
 large-T-cell, lymphomatoid papulosis and, 2138
 nasal-type natural killer/T-cell, in Koreans, 2106
 natural killer precursor, in Koreans, 2106
 in offspring of women with colorectal cancer, 741
 primary cerebral, radiation therapy with/without chemotherapy for, 1359
 primary extranodal, soluble intercellular adhesion molecules-1 in, prognosis and, 1387
 survival in, in U.S. vs. Europe, 893
 testicular, extranodal recurrence of, 713 (letter)
 Lymphomatoid papulosis
 with hypereosinophilic syndrome and large T-cell lymphoma, 2138
 interferon- α for, 1603
 Lymphopenia, docetaxel-induced, 1380

M

Macrophage migration inhibitory factor, in lung cancer, prognosis and, 334
 Malignant biliary obstruction, chemoradiation for, 29
 Malignant melanoma. *See* Melanoma
 Mammography
 in Asian American and Pacific Islanders, 696
 CEA immunoscintigraphy with, 104
 Managed care, breast cancer outcome and, 2202
 Mania, interferon-alpha-2b and, 356
 Mapping
 of disease foci, in prostate biopsy, 1800
 lymphatic, in skin cancer, 236
 Markers. *See* Tumor markers
 Mastectomy
 for breast cancer, in older women, 561
 radiation therapy after, axillary node extranodal soft tissue extension and, 223 (letter)
 Matrix metalloproteinase 9, in nasopharyngeal cancer, metastasis and, 715
 Maxillary sinus cancer, combined treatment for, 1925
 Mayo Lung Project, 2352
 McGill Quality of Life Questionnaire, 1854
 M.D. Anderson Symptom Inventory, 1634
 MDM-2, in acute myelogenous leukemia, prognosis and, 1976
 mdm2, in bladder cancer, prognosis and, 619
 Medicare, breast cancer outcome and, 2202
 Melanoma

- cisplatin-dacarbazine-fomustine with interferon- α for, 2630
- cutaneous
- patient detection patterns in, 342
 - recurrent, interferon- α for, 1490
 - resection margins for, 1495
- distant metastasis in, surgery for, 1983
- interferon-alpha-2b for, mania and bipolar syndromes and, 356
- intratumoral injection of dendritic cells for, 2646
- lymphatic mapping in, 236
- metastatic uveal, postresection survival in, 1561
- mortality trends in, in Sweden, 348
- nodular, c-MYC in, 97
- selective lymph node dissection for, patient selection for, 453
- sentinel/completion lymphadenectomy for, 236
- sentinel node biopsy in
- frozen section analysis of, 1720
 - patient selection for, 453
- stage III, PET scanning in, 1019
- survival in, in U.S. vs. Europe, 893
- time trends of, in Australia and Central Europe, 1269
- Memorial Symptom Assessment Scale Short Form (MSAS-SF), 1162
- Meningioma
- Ets-1 transcription factor in, 2292
 - recurrence of, vascular endothelial growth factor and, 1102
 - telomerase activity and telomere length in, 2092
 - urokinase-type plasminogen activator in, 2292
- Merkel cell carcinoma, 1866 (letter)
- Mesothelioma, peritoneal, early localized, 1279
- Messenger RNA
- carcinoembryonic antigen, in colorectal cancer, prognosis and, 970
 - transforming growth factor- α , in chronic hepatitis and hepatocellular carcinoma, 977
- Metastasis
- biliary tract, from gastric cancer, chemoradiation for, 29
 - cerebral
 - from prostate cancer, 706 (letter)
 - from unknown primary, 1095 - from colorectal cancer, tumor thickness and, 35
 - gastric, in breast cancer, presentation, endoscopic features and treatment of, 2214
 - hepatic, in colorectal cancer
 - blood flow in, 1236
 - distribution of, 285
 - fibrous pseudocapsule of, 257
 - microwave coagulation therapy for, 276
 - pharmacokinetic modulating chemotherapy for, 1228
 - tumor thickness and, 35
 - vascular endothelial growth factor and, 488 - immune surveillance and, 1626
 - lymph node
 - in breast cancer
 - axillary extranodal soft tissue extension of, 223 (letter)
 - computer simulations, 2527
 - computer simulations of, 2527
 - in sentinel vs. nonsentinel nodes, 574 - from colorectal cancer, tumor thickness and, 35
 - in esophageal cancer
 - KAI1/CD82 and, 955
 - localization of, 1869 - in esophageal squamous cell carcinoma, KAI1/CD82 and, 955
 - in esophagogastric junction adenocarcinoma, 1874
 - in gastric cancer, in Japan vs. U.S., 2237
 - localization of, in esophageal cancer, 1869
 - in nasopharyngeal cancer, latent membrane protein 1 and matrix metalloproteinase 9 and, 715 - in melanoma, surgery for, 1983
 - micrometastasis, vs. isolated tumor cells, 707, 709 (letters)
 - in nasopharyngeal cancer, latent membrane protein 1 and matrix metalloproteinase 9 and, 715
 - pancreatic, from renal cell carcinoma, 1076
 - pulmonary, hepatoblastoma presenting as, 1845
 - skeletal
 - in breast cancer, predictors of, 363
 - in soft tissue sarcoma, routine scintigraphy for, 1726 - susceptibility to, PET study of, 1626
- Methotrexate
- for acute lymphoblastic leukemia, hypomethylation and, 925
 - for breast cancer, with cyclophosphamide and 5-fluorouracil, 2521
- 2-Methoxyestradiol, for hepatoma, 983
- Methylation, acute lymphoblastic leukemia-associated leukoencephalopathy and, 925
- MIB-1
- in bile duct papillary carcinoma, 508
 - in radiation-treated cervical cancer, 1526
 - recurrent meningioma and, 1102
- Microcarcinoids, duodenal, 963
- Micrometastasis. *See also* Metastasis
- vs. isolated tumor cells, 707, 709 (letters)
 - lymph node, in esophagogastric junction adenocarcinoma, 1874
- Microsatellite instability
- in colorectal cancer, clinicopathologic correlates of, 2025
 - in endometrial cancer
 - analysis at 10q25-q26 and, 1773
 - clinical significance of, 1758
- Microwave coagulation therapy
- for hepatic metastasis, in colorectal cancer, 276
 - transcatheter arterial chemoembolization, for hepatocellular carcinoma, 1245
- Mitoxantrone, reduced efficacy of, after pneumoperitoneum, 262

Monoclonal antibodies, for prostate cancer, 1329
 Monoclonal antibody IMC-C225, inhibition of pancreatic tumor growth by, 74
 Monoclonal antibody single chain Fv fragment, in immunofluorescent tumor localization, 1134
 Mood instability. *See also* Emotional status
 interferon- α -2b and, 356
 Morphine, in hospice setting, 220 (letter)
 Mortality, in U.S. vs. Europe, 893
 mRNA

 carcinoembryonic antigen, in colorectal cancer, prognosis and, 970
 transforming growth factor- α , in chronic hepatitis and hepatocellular carcinoma, 977
 Mucin, gastric type, in differentiated type early gastric carcinoma, 724
 Mucositis, oropharyngeal, salivary epidermal growth factor and, 2258
 Musculoskeletal masses, percutaneous needle biopsy of, 2677
 Myeloid leukemia, erythroid differentiation in, proline-directed protein kinase F_A and, 1004
 Myeloproliferative syndrome, new hematopoietic cell line with endothelial features from, 221 (letter)
 Myogenic tumors of bone, post-transplant, Epstein-Barr virus in, 467

N

Narcotics, in hospice setting, 220 (letter)
 Nasal-type natural killer/T-cell lymphoma, in Koreans, 2106
 Nasopharyngeal cancer. *See also* Head and neck cancer
 metastasis in, latent membrane protein 1 and matrix metalloproteinase 9 and, 715
 pediatric, chemoradiotherapy for, 680
 staging of, UICC vs. Chinese system for, 242
 survival in, in India, 437
 National Cancer Institute
 cooperative early lung cancer detection program of, 2349
 New York screening program of, 2356
 National Ovarian Cancer Survey, symptoms and diagnosis in, 2068
 Native Americans, stage at diagnosis, treatment, and survival in, 181
 Natural killer precursor lymphoma, in Koreans, 2106
 Nausea, chemotherapy-induced, ganisetron vs. ondansetron for, 2301
 Neck, follicular dendritic cell sarcoma of, 664
 Nerve injury, during hysterectomy, 834, 2144 (erratum)
 Netherlands, very elderly in, cancer incidence in, 1121
 Neurilemoma, with angiosarcoma, 1577
 Neuroblastoma, granulocyte-colony stimulating factor with chemotherapy for, 2122
 Neurocytoma, benign central, 1111
 Neuroendocrine-like differentiation, in pancreatic cancer, 2230

Neutropenia, fungal infections in, oral fluconazole prophylaxis for, 1611
 Neutrophil hyperfunction, in BCR/ABL negative chronic myeloid leukemia, 561
 Nipple discharge, fiberoptic ductoscopy for, 1512
 Nodal metastasis. *See* Lymph node metastasis
 Nodular ganglioneuroblastoma, prognostic subsets of, 1150
 Nodular melanoma, c-MYC in, 97
 Non-Hodgkin's lymphoma. *See* Lymphoma
 Norway, cervical adenocarcinoma in, increasing incidence of, 1291
 NovoMab-G2-scFv-Cy5.5 complex, in immunofluorescent tumor localization, 1134
 Nuclear factor κ B, in hepatocellular carcinoma, 2266
 Nuclear ribonucleoprotein A2/B1, in lung cancer screening, 2465
 Nurses, oncology, smoking cessation interventions by, 881
 Nutrients, plasma, as cervical dysplasia marker, 376
 Nutrition, gastric cancer survival and, 1205

O

Oncology nurses, smoking cessation interventions by, 881
 Ondansetron, for chemotherapy-induced nausea and vomiting, 2301
 Opioids, in hospice setting, 220 (letter)
 Oral/oropharyngeal cancer, radiotherapy for, mucositis in, salivary epidermal growth factor and, 2258
 Oral/oropharyngeal cancer. *See also* Head and neck cancer
 bone invasion in, interleukin-6 enhancement of, 1966
 preoperative chemotherapy followed by chemoradiotherapy for, 939
 survival in, in India, 437
 verrucous, c-erbB-3 in and proliferating cell nuclear antigen in, 2597
 Organophosphate exposure, pediatric non-Hodgkin's lymphoma and, 2315
 Osteoclastic bone resorption, in oral cancer, interleukin-6 enhancement of, 1966
 Osteonecrosis, of femoral head, in interferon-treated chronic myeloid leukemia, 1482
 Osteosarcoma
 chemotherapy for, reproductive function after, 1961
 metastatic, retinoic acid and interferon- α for, 2661
 Ovarian cancer
 germ cell, conservative surgery for, 391
 markers of, in BRCA1 heterozygotes, 383
 microinvasive mucinous, classification and prognostic significance of, 1541
 p53 alterations in, prognosis and, 2006
 screening for, via transvaginal ultrasonography, 582
 Stage III/IV, paclitaxel, cisplatin and epirubicin for, 1547
 steroid receptor status in, prognosis and, 1783
 surgical outcome in, CT-based prediction of, 1532

- survival in, in U.S. vs. Europe, 893
- symptoms and diagnosis of, 2068
- Ovarian function, after chemotherapy, for osteosarcoma, 1961
- Ovary, premalignant changes in *BRCA1* heterozygotes, 383

P

- p16 inactivation, in hepatocellular carcinoma, 60
- p16/p14 locus deletion, in acute myelogenous leukemia, prognosis and, 1976
- p21
 - in bladder cancer, prognosis and, 619
 - in cervical squamous cell carcinoma, 1300
 - in Ewing's sarcoma, prognosis and, 783
- p27^{Kip1}, in gastric cancer, prognosis and, 1684, 2247
- p53
 - in bile duct papillary carcinoma, 508
 - in bladder cancer, prognosis and, 619
 - in cervical squamous cell carcinoma, 1300
 - in colorectal cancer, paclitaxel radiosensitization effect and, 1893
 - in ductal carcinoma in situ, 2153
 - in Ewing's sarcoma, prognosis and, 783
 - in gastric cancer
 - P-glycoprotein and, 21
 - prognosis and, 2247
 - in hepatocellular carcinoma, in India, 2322 (letter)
 - KAI1/CD82 and, in esophageal squamous cell carcinoma, 955
 - in nonsmall cell lung cancer
 - paclitaxel response and, 769
 - tumor kinetics and chromosomal instability and, 1933
 - in ovarian cancer, prognosis and, 2006
 - in ovarian tissue, in *BRCA1* heterozygotes, 383
 - in renal cell carcinoma, DNA content and, 1065
- p53 antibody, in esophageal cancer, 1677
- Pacific Islanders. *See also* Asians
 - screening for breast and cervical cancer in, 696
- Paclitaxel
 - for breast cancer, 2169
 - in refractory disease, 2195
 - for cancer of unknown primary site, 2655
 - for colorectal cancer, radiosensitizing effect of, p53 and, 1893
 - for head and neck cancer, in induction therapy, 2587
 - for hepatoma, 983
 - for metastatic lung cancer, 2622
 - for nonsmall cell lung cancer, 89
 - with ifosfamide and cisplatin, 774
 - p53 mutations and, 769
 - with radiotherapy, 534
 - for ovarian cancer, 1547
 - for prostate cancer, in weekly 1-hour infusion, 431, 1412 (erratum)
- Pain management
 - consultation for, outcome of, 920
 - morphine in hospice setting and, 220 (letter)
- Palliative care. *See also* Pain management
 - morphine in, 220 (letter)
 - symptom assessment in, Memorial Symptom Assessment Scale Short Form (MSAS-SF) for, 1162
- Palliative prognostic (PaP) score, delirium and, 1145
- Pancreatic cancer
 - arterial infusion chemotherapy for, 303
 - delayed ¹⁸F-fluoro-2-deoxy-D-glucose PET in, 2547
 - gemcitabine and leucovorin-modulated UFT for, 1706
 - glutathione in, 1440
 - high-dose conformal radiotherapy for, 2222
 - inhibition of by antibody IMC-C225, 74
 - initial treatment of, with chemoradiotherapy vs. resection, 314
 - neuroendocrine-like differentiation in, 2230
 - RNase 1 expression in, 1252
 - tissue polypeptide specific antigen in, 83
 - treatment of, cost analysis of, 1917
- Pancreatic metastasis, from renal cell carcinoma, 1076
- Pancreatoduodenectomy, as initial treatment, vs. chemoradiotherapy, 314
- Papanicolaou smear
 - alternatives to, in resource-poor settings, 826
 - in Asian American and Pacific Islanders, 696
 - vs. direct visual inspection, 826
- Papillomatosis, biliary, intraluminal iridium-192 for, 69
- Paraganglioma, carotid body, vs. schwannoma with angiosarcoma, 1577
- Paranasal sinus cancer, combined treatment for, 1925
- Parotid gland cancer
 - Frey syndrome and, botulinum toxin for, 1659
 - resection of, Frey syndrome after, botulinum toxin for, 1659
 - TNM classification of, 1664
- Partial cystectomy, for bladder cancer, population-based study of, 142
- Pathologic fractures, in breast cancer, predictors of, 363
- Pathology
 - International Union Against Cancer Telepathology Consultation Center for, 187
 - surgical, mandatory second opinion and, 295 (letter)
- Pediatric cancer. *See* Children and specific cancers
- Pegylated liposomal doxorubicin, for breast cancer, 1037
- Pelvic nerve plexus, trauma to, during hysterectomy, 834, 2144 (erratum)
- Percutaneous microwave coagulation therapy, transcatheter arterial chemoembolization, for hepatocellular carcinoma, 1245
- Percutaneous needle biopsy, of musculoskeletal masses, 2677
- Performance status, symptom distress and, 1634
- Peritoneal mesothelioma, early localized, 1279
- Pesticide exposure, pediatric non-Hodgkin's lymphoma and, 2315
- P-glycoprotein, in gastric cancer, p53 and, 21
- Pharmacokinetic modulating chemotherapy, for hepatic colorectal metastasis, 1228

- Photodynamic therapy, for occult squamous cell carcinoma of lung, 2445
- Pilocystic astrocytoma, pathologic classification of, 1569
- Pipelle device, for endometrial sampling, diagnostic yield of, 1765
- Plasma nutrients, as cervical dysplasia marker, 376
- Pleuropulmonary blastoma, management and prognosis of, 1396
- Ploidy. *See* DNA content
- Pneumoperitoneum, increased tumor growth and decreased chemotherapy efficacy after, 262
- Polymerase chain reaction
- random arbitrarily primed, for glyceraldehyde-3-phosphate dehydrogenase, in renal cell carcinoma, 152
 - real-time, for estrogen receptor- α/β mRNA expression, in breast cancer, 1732
 - reverse-transcriptase
 - for prostate cancer, 2577
 - for soft tissue sarcoma, 1992
- Positron emission tomography
- ^{18}F -fluoro-2-deoxy-D-glucose, in pancreatic cancer, 2547
 - 2-fluorine-18, 2-fluoro-2-deoxy-D-glucose, in melanoma, 1019
 - metastatic susceptibility and, 1626
- Poverty
- breast cancer outcome and, 1593, 2202
 - cancer incidence and, in Canada vs. U.S., 901
 - cervical cancer outcome and, 1593
- Prednisone, for cerebral lymphoma, with radiation therapy, 1359
- Pregnancy, trophoblast malignant transformation in, cyclin E and, 673
- Progesterone receptor status, in ovarian cancer, prognosis and, 1783
- Prognosis. *See specific cancers*
- Proliferating cell nuclear antigen
- in congenital sacrococcygeal teratoma, 932
 - in verrucous oral cancer, 2597
- Proline-directed protein kinase F_{A} , erythroid differentiation in myeloid leukemia cells and, 1004
- Prostate biopsy
- detailed mapping of disease foci in, 1800
 - postbrachytherapy, disease and treatment effects on, 1829
 - single microscopic focus on, postoperative outcome and, 1810
- Prostate cancer
- androgen-independent metastatic, vinorelbine and estramustine for, 1824
 - antiangiogenic therapy for, 1329
 - antioxidant enzymes in, 123
 - biologic therapy for, 1329
 - biopsy in. *See* Prostate biopsy
 - brain metastasis from, 706 (letter)
 - cyclooxygenase-2 in, 589
 - disease foci mapping in, 1800
 - early stage, treatment costs in, 1792
 - gene therapy for, 1329
 - grading of, Web-based tutorial for, 1818
 - hereditary, breast and gastric cancer and, 1315
 - hormone-refractory, low-dose dexamethasone for, 2570
 - hypoxia in, stage and patient age and, 2018
 - immunotherapy for, 1329
 - in Ivory Coast, 653
 - loss of tissue transglutaminase in, 412
 - monoclonal antibodies for, 1329
 - node-negative, with seminal vesicle invasion, staging of, 2577
 - novel strategies for, 1329
 - paclitaxel for, in weekly 1-hour infusion, 431, 1412 (editorial)
 - postoperative disease-free survival in, modeling of, 232, 234 (editorials)
 - prognostic classification in, recursive partitioning analysis for, 404
 - prostate specific antigen in, adjusted for transition zone volume, 842
 - radiation therapy for
 - brachytherapy, 135
 - effects of on biopsy results, 1829
 - prostatourethral-rectal fistula after, 2085
 - with hyperthermia, 399
 - quality of life and, 1322
 - 3-D conformal, 2565
 - with single microscopic focus, outcome of after radical prostatectomy, 1810 - strontium-89 for, acute myelogenous leukemia after, 226 (letter)
 - surgery for. *See* Prostatectomy
 - survival in
 - modeling of, 232, 234 (editorials)
 - in U.S. vs. Europe, 893
 - tumor volume in, morphometric measurement of, 1056
 - visual estimate of percentage of carcinoma in prostatectomy specimens from, prognosis and, 1308
- Prostatectomy, radical
- disease-free survival after, modeling of, 232, 234 (editorials)
 - for disease with single microscopic focus, outcome after, 1810
 - length of hospital stay for, 424
- Prostate specific antigen
- adjusted for transition zone volume, 842
 - after radical prostatectomy, 1810
- Prostate specific membrane antigen, monoclonal antibodies to, for prostate cancer, 1329
- Prostatic intraepithelial neoplasia, antioxidant enzymes in, 123
- Prostatourethral-rectal fistula, after brachytherapy, 2085
- Proteases, cellular, in chondrosarcoma, 995
- Psychiatric side effects, of interferon- α -2b, 356
- Psychosocial group intervention, for breast cancer patients, in Japan, 1026

Psychosocial issues

- for breast cancer patients
 - in Japan, 1026
 - persistent functional health changes and, 2176
- depression after successfully treated lung cancer, 1172
- in gynecologic cancer, with extensive chemotherapy, 1402
- personal account of, 229
- in prostate cancer, before/after radiation therapy, 1322
- in successfully treated lung cancer, 1172
- Pulmonary alveolar proteinosis, in BCR/ABL negative chronic myeloid leukemia, neutrophil hyperfunction in, 561
- Pulmonary metastasis, hepatoblastoma presenting with, 1845
- Pyloric gland metaplasia, duodenal carcinoids and, 963

Q

Quality of life

- in breast cancer, persistent changes in, 2176
- in chemotherapy-treated gynecologic cancer, 1402
- McGill Quality of Life Questionnaire for, 1854
- Memorial Symptom Assessment Scale Short Form (MSAS-SF) for, 1162
- in radiation-treated prostate cancer, 1322
- symptom distress and, 1634

R

Race

- bladder cancer stage at diagnosis and, 1349
- breast cancer outcome and, 2202

Radiation therapy

- for bladder cancer
 - with chemotherapy, 1089
 - population-based study of, 142
- brachytherapy
 - with intraluminal iridium-192, for biliary papillomatosis, 69
 - for prostate cancer, 135
 - effects of on biopsy results, 1829
 - prostatourethral-rectal fistula after, 2085
- for breast cancer, in older women, 561
- for cerebral lymphoma, with/without chemotherapy, 1359
- for cervical cancer, high growth fraction at 9 Gy in, prognosis and, 1526
- for colorectal cancer, paclitaxel radiosensitizing effect for, p53 and, 1893
- for cystosarcoma phyllodes of breast, 1502
- for esophageal cancer, with chemotherapy, 946, 2144 (erratum)
- for extrahepatic biliary tract recurrence of gastric cancer, with chemotherapy, 29
- for head and neck cancer
 - with carboplatin, 2099
 - with chemotherapy, 939
- intraluminal iridium-192, for biliary papillomatosis, 69
- for maxillary sinus cancer, 1925

- for nonsmall cell lung cancer
 - in elderly, 1953
 - in induction therapy, 1946
- oropharyngeal, mucositis in, salivary epidermal growth factor and, 2258
- for pancreatic cancer
 - cost analysis for, 1917
 - high-dose conformal, 2222
 - in induction therapy, vs. resection, 314
- patient's experience of, 229
- for pediatric nasopharyngeal cancer, with chemotherapy, 690
- postmastectomy, axillary node extranodal soft tissue extension and, 223 (letter)
- for prostate cancer
 - acute myelogenous leukemia after, 226 (letter)
 - with hyperthermia, 399
 - quality of life and, 1322
 - 3-D conformal, 2565
- for retinoblastoma, with metastasis, 2117
- Radical hysterectomy, pelvic nerve plexus trauma during, 834
- Radical prostatectomy
 - disease-free survival after, modeling of, 232, 234 (editorials)
 - for disease with single microscopic focus, outcome after, 1810
 - length of hospital stay for, 424
- Radiography, chest
 - in lung cancer screening. *See* Lung cancer, screening for
 - radiation exposure in, 2457
- Radioimmunoguided surgery, for colorectal cancer, 1692
- Radioisotope scanning, of bone, in soft tissue sarcoma staging, 1726
- Radiosurgery, for brain metastasis, from unknown primary, 1095
- Radon, lung cancer and, in German uranium workers, 2613
- Raltitrexed, liver failure and, 890
- Random arbitrarily primed polymerase chain reaction, for glyceraldehyde-3-phosphate dehydrogenase, in renal cell carcinoma, 152
- Rectal cancer. *See* Colorectal cancer
- Relaxin-like factor
 - in breast cancer, 2161
 - in normal vs. neoplastic breast tissue, 2161
- Renal cell carcinoma
 - DNA content in, p53 and *bcl-2* and, 1065
 - glyceraldehyde-3-phosphate dehydrogenase in, 152
 - histologic classification and TNM staging of, prognosis and, 604
 - infusional interleukin-2 and 5-fluorouracil plus subcutaneous interferon- α for, 597
 - metastatic, bryostatin-1 for, 615
 - pancreatic metastasis in, 1076
 - smoking and, 630

Reproductive function, after chemotherapy, for osteosarcoma, 1961
 Retinoblastoma, metastatic, chemoradiotherapy for, 2117
 Retinoic acid, with interferon- α , for metastatic osteosarcoma, 2661
 RET mutation carriers, of familial medullary thyroid carcinoma syndrome, thyroidectomy for, 863
 Reverse-transcriptase polymerase chain reaction assay for carcinoembryonic antigen mRNA, in colorectal cancer, 970
 for prostate cancer, 2577
 for soft tissue sarcoma, 1992
 Ribonuclease 1, in pancreatic cancer, 1252
 Rituximab, for cutaneous B-cell lymphoma, 1835
 mRNA
 carcinoembryonic antigen, in colorectal cancer, prognosis and, 970
 transforming growth factor- α , in chronic hepatitis and hepatocellular carcinoma, 977
 RNase 1 expression, in pancreatic cancer, 1252
 Roentgenography, chest
 in lung cancer screening. *See* Lung cancer, screening for
 radiation exposure in, 2457
 Role functioning, in prostate cancer, before/after radiation therapy, 1322

S

Sacroccygeal teratoma, congenital, DNA ploidy in, 932
 S-adenosylhomocysteine, acute lymphoblastic leukemia-associated leukoencephalopathy and, 925
 S-adenosylmethionine, acute lymphoblastic leukemia-associated leukoencephalopathy and, 925
 Salivary epidermal growth factor, mucositis and, in oropharyngeal radiation therapy, 2258
 Salivary gland cancer
 Frey syndrome and, botulinum toxin for, 1659
 pediatric, Epstein-Barr virus and, 463
 TNM classification of, 1664
 treatment results and prognostic factors in, 1195
 Saphenous vein preservation, in inguinal lymphadenectomy, in vulvar cancer, 1520
 Sarcoma. *See also specific types, e.g.,* Chondrosarcoma
 Ewing's
 INK4A deletion in, prognosis and, 783
 p53 in, prognosis and, 783
 follicular dendritic cell, of neck, 664
 head and neck, prognostic factors in, 868
 Kaposi, in Ivory Coast, 653
 osteogenic
 chemotherapy for, reproductive function after, 1961
 metastatic, retinoic acid and interferon- α for, 2661
 soft tissue
 etoposide, ifosfamide and cisplatin for, 177
 reverse-transcriptase PCR assay for, 1992
 staging of, bone scintigraphy in, 1726
 Schwannoma, with angiosarcoma, 1577
 Scintigraphy, bone, in soft tissue sarcoma staging, 1726

Screening

for breast cancer
 in Asian American and Pacific Islanders, 696
 CEA immunoscintigraphy with, 104
 for cervical cancer
 in Asian American and Pacific Islanders, 696
 direct visual inspection vs. Pap smear for, 826
 in resource-poor settings, 826
 in developing countries, 475
 for lung cancer, 2334
 bias in, 2369
 computed tomography in, in Japan, 2485
 cost-effectiveness of, 2502
 in Germany, 2494
 in Japan, 2489
 in Czechoslovakia, 2363
 Early Lung Cancer Action Project for, 2474
 fluorescence bronchoscopy in, 2468
 in Italy, 2345
 in Japan, 2392, 2485, 2489
 Mayo Lung Project for, 2352
 molecular methods in, 2465
 NCI cooperative program for, 2349
 NCI New York study of, 2356
 overdiagnosis in, 2369, 2422, 2432
 randomized trials of, 2397, 2399, 2422, 2449
 sensitivity and specificity in, 2453
 sputum cytology in, 2461
 survival and, 2369, 2387, 2422
 for ovarian cancer, via transvaginal ultrasonography, 582
 Second primary, breast cancer as, 1999
 Secretory leukoprotease inhibitor, in nonsmall cell lung cancer, 1448
 Selective lymphadenectomy, in melanoma, patient selection for, 453
 Sentinel lymphadenectomy
 indications and technique for, 236
 for skin cancer, 236
 Sentinel node biopsy
 in breast cancer
 computer simulations for, 2187
 false negative, after preoperative chemotherapy, 2187
 in melanoma
 frozen section analysis of, 1720
 patient selection for, 453
 Sentinel node metastasis, in breast cancer, nonsentinel node metastasis and, 574
 Serum markers. *See specific markers*
 Single photon emission computed tomography, gallium-67, for Hodgkin's disease, correlation of with CT and lymphangiography, 1371
 Skeletal metastasis
 in metastatic breast cancer, predictors of, 363
 in soft tissue sarcoma, routine scintigraphy for, 1726
 Skin cancer. *See also* Melanoma
 basal cell, clustering of, 1012

- lymphatic mapping in, 236
 - sentinel/completion lymphadenectomy for, 236
 - Small intestinal toxicity, of 5-fluorouracil, 711 (letter)
 - Smoking
 - cessation of, lung cancer risk after, 2505
 - interventions for by oncology nurses, 881
 - postoperative survival in nonsmall cell lung cancer and, 1457
 - radon exposure and, lung cancer histopathology and, 2613
 - screening for lung cancer and. *See* Lung cancer, screening for
 - urinary tract cancer and, 630
 - Socioeconomic status
 - breast cancer outcome and, 1593, 2202
 - cancer incidence and, in Canada vs. U.S., 901
 - cervical cancer outcome and, 1593
 - Soft tissue sarcoma
 - etoposide, ifosfamide and cisplatin for, 177
 - reverse-transcriptase PCR assay for, 1992
 - staging of, bone scintigraphy in, 1726
 - Soluble intercellular adhesion molecules-1, in extranodal non-Hodgkin's lymphoma, prognosis and, 1387
 - SPECT, gallium-67, for Hodgkin's disease, correlation of with CT and lymphangiography, 1371
 - Spinal cord compression, in breast cancer, predictors of, 363
 - Splenic arterial infusion chemotherapy, for pancreatic cancer, 303
 - Sputum cytology, in lung cancer screening, 2461
 - Squamous cell carcinoma. *See also specific sites*
 - ascorbic acid accumulation in, 171
 - Staging
 - of hepatocellular carcinoma, 2266
 - of nasopharyngeal cancer, UICC vs. Chinese system for, 242
 - of prostate cancer, 2577
 - of renal cell carcinoma, 604
 - of salivary gland cancer, 1664
 - of soft tissue sarcoma, bone scintigraphy in, 1726
 - Stem cell transplantation
 - for chronic myeloid leukemia, in younger patients, 1647
 - for HIV-associated non-Hodgkin's lymphoma, 680
 - Steroid receptor status, in ovarian cancer, prognosis and, 1783
 - Stomach. *See under* Gastric
 - Stool guaiac test, vs. immunochemical occult blood test, sensitivity of, 46
 - Strontium-89, for prostate cancer, acute myelogenous leukemia after, 226 (letter)
 - Sudation parotidienne, botulinum toxin for, 1659
 - Superior vena cava syndrome, in angiotrophic large cell lymphoma, 2515
 - Surgery. *See also specific cancers and procedures*
 - for bladder cancer, population-based study of, 142
 - for breast cancer, in older women, 561
 - conservative, for ovarian germ cell tumors, 391
 - for distant metastases, in melanoma, 1983
 - for gastric cancer
 - early and late recurrence after, 255
 - prophylactic radical lymphadenectomy, 1425
 - laparoscopic, pneumoperitoneum for, tumor cell growth and chemotherapy efficacy after, 262
 - for prostate cancer
 - disease-free survival after, modeling of, 232, 234 (editorials)
 - for disease with single microscopic focus, outcome after, 1810
 - length of hospital stay for, 424
 - radioimmunoguided, for colorectal cancer, 1692
 - videothoracoscopic, vs. open resection, for lung cancer, 2497
 - Surgical margins, in ductal carcinoma in situ, 2323
 - Surgical pathology, mandatory second opinion and, 295 (letter)
 - Survival, in U.S. vs. Europe, 893
 - Sweating, gustatory, botulinum toxin for, 1659
 - Sweden
 - familial colorectal cancer in, 741
 - melanoma mortality trends in, 348
 - Sweet syndrome, in BCR/ABL negative chronic myeloid leukemia, neutrophil hyperfunction in, 561
 - Symptoms
 - Memorial Symptom Assessment Scale Short Form (MSAS-SF) for, 1162
 - severity of and impact of, assessment tool for, 1634
- T**
- Taiwan, lymphoma epidemiology in, 1586
 - Tamoxifen, for breast cancer, uterine cancer surveillance after, 800
 - Taurolidin, post-pneumoperitoneum survival time and, 262
 - T-cell lymphoma, lymphomatoid papulosis and, 2138
 - T-cell proliferation, in B-cell chronic lymphoproliferative disorders, B7 molecules and, 1259
 - Telomerase
 - in B-cell non-Hodgkin's lymphoma, 445
 - in meningioma, 2092
 - Teratoma, congenital sacrococcygeal, DNA ploidy in, 932
 - Testicular lymphoma, extranodal recurrence of, 713 (letter)
 - 3p23, loss of heterozygosity at, in colorectal cancer, prognosis and, 1220
 - Thromboembolism, venous, gliomas and, 640
 - Thymidylate synthase quantitation, for hepatic arterial infusion chemotherapy, 288
 - Thymoma, vs. follicular dendritic cell sarcoma of neck, 664
 - Thyroid cancer
 - familial medullary, RET mutation carriers of, thyroidectomy for, 863
 - in Germany
 - patterns of care for, 192
 - vs. in U.S., 1

prospective cohort studies of, 192, 202
 Thyroidectomy, for RET mutation carriers, in familial medullary thyroid carcinoma syndrome, 863
 Tissue polypeptide specific antigen, in pancreatic cancer, 83
 Tissue transglutaminase, loss of, as prostate cancer marker, 412
 TNM staging. *See also* Staging
 of renal cell carcinoma, 604
 of salivary gland cancer, 1664
 Tobacco use. *See* Smoking
 Tongue, cancer of. *See also* Head and neck cancer
 survival in, in India, 437
 Total cystectomy, for bladder cancer, population-based study of, 142
 Transcatheter arterial chemoembolization
 for pancreatic cancer, 303
 with percutaneous microwave coagulation therapy, for hepatocellular carcinoma, 1245
 preoperative, in hepatocellular carcinoma, 2606
 Transforming growth factor- β 1-binding protein, carmustine resistance and, 850
 Transforming growth factor- α mRNA, in chronic hepatitis and hepatocellular carcinoma, 977
 Transglutaminase, loss of, as prostate cancer marker, 412
 Transplantation
 myogenic tumors of bone after, Epstein-Barr virus in, 467
 stem cell
 for chronic myeloid leukemia, in younger patients, 1647
 for HIV-associated non-Hodgkin's lymphoma, 680
 Transurethral resection of bladder, population-based study of, 142
 Transvaginal ultrasonography, in ovarian cancer screening, 582
 Treatment. *See also specific modalities*
 toxicity of, severity and impact of, 1634
 Treatment compliance, use of alternative therapies and, 873
 Trofosfamide, for glioblastoma multiforme, 2131
 Trophoblasts, neoplastic transformation of, cyclin E and, 673
 Tumor cells, isolated, vs. micrometastasis, 707, 709 (letters)
 Tumor localization, immunofluorescent, using single chain Fv fragment of monoclonal antibody, 1134
 Tumor markers. *See also specific markers and cancers*
 in pancreatic cancer, 83
 Turkey, gastric lymphoma in, 12
 Tutorial, Web-based, for prostate cancer grading, 1818

U

UFT
 for hepatic colorectal metastasis, 1228
 leucovorin-modulated, with gemcitabine, for pancreatic cancer, 1706

UICC staging system, for nasopharyngeal cancer, vs. Chinese system, 242
 UICC Telepathology Consultation Center, 187
 Ulcerative colitis-associated colorectal cancer, cell adhesion molecules in, 733
 Ultrasonography, transvaginal, in ovarian cancer screening, 582
 Uranium workers, lung cancer histopathology, 2613
 Ureteral cancer, smoking and, 630
 Urethral cancer, smoking and, 630
 Urinary tract cancer, smoking and, 630
 Urokinase plasminogen activator, in chondrosarcoma, 995
 Urokinase-type plasminogen activator, in meningioma, 2292
 Urologic cancer, smoking and, 630
 Uterine cancer
 c-ets1 in, 2059
 endometrial sampling in, diagnostic yield of, 1765
 microsatellite instability in
 analysis at 10q25-q26 and, 1773
 clinical significance of, 1758
 surveillance for, in tamoxifen-treated breast cancer survivors, 800
 survival in, in U.S. vs. Europe, 893
 Uterine cervix. *See under* Cervical
 Uterine supporting ligaments, pelvic nerve plexus trauma and, during hysterectomy, 834
 Uveal melanoma, metastatic, postresection survival in, 1561

V

Vascular endothelial growth factor
 in antiangiogenic gene therapy, 1181
 in colorectal cancer liver metastasis, 488
 recurrent meningioma and, 1102
 Vectors, for antiangiogenic gene therapy, 1181
 Venous thromboembolism, gliomas and, 640
 Verrucous oral cancer, *c-erbB-3* and proliferating cell nuclear antigen in, 2597
 Videothoroscopic surgery, vs. open resection, for lung cancer, 2497
 Vincristine
 for cerebral lymphoma, with radiation therapy, 1359
 for metastatic retinoblastoma, 2117
 for neuroblastoma, with granulocyte-colony stimulating factor, 2122
 Vinorelbine
 with gemcitabine, for nonsmall cell lung cancer, 763
 for prostate cancer, 1824
 VIP regimen, for soft tissue sarcoma, 177
 Viral vectors, for antiangiogenic gene therapy, 1181
 Vitamin B₁₂, as cervical dysplasia marker, 376
 Vomiting, chemotherapy-induced, ganisetron vs. ondansetron for, 2301
 VP 16. *See* Etoposide

Vulvar cancer
 inguinal lymphadenectomy for, saphenous vein preservation in, 1520
 squamous cell, recurrence of, 116

W

Waldeyer ring lymphoma, soluble intercellular adhesion molecules-1 in, prognosis and, 1387
Web-based tutorial, for prostate cancer grading, 1818
Weight, breast cancer risk and, 369
West Africa, cancer incidence in, 653

X

X-rays, chest
 in lung cancer screening. *See* Lung cancer, screening for
 radiation exposure from, 2457

Y

Young adults, salivary gland tumors in, Epstein-Barr virus in, 463

Authors' Index—Volume 89

A

Abdel-Nabi, H., 104
 Abe, H., 963
 Abeler, V. M., 1291, 2076
 Abramson, A. F., 2538
 Abramson, D. H., 2117
 Adachi, Y., 255, 1418
 Adami, F., 1259
 Adham, M., 946
 Adoubi, I., 653
 Aftanas, A., 1134
 Agostini, C., 1259
 Agrawal, A., 2587
 A'Hern, R. P., 834
 Ahlert, C., 262
 Ahmed, M. M., 1893
 Ahnoux, A. A., 653
 Aikou, T., 1214
 Aisner, S. C., 1953
 Aizawa, S., 1541
 Aizawa, Y., 53
 Akan, H., 1474
 Akechi, T., 1172
 Akerley, W., 769
 Akiyama, H., 1611
 Akiyama, T., 303
 Akizuki, N., 1172
 Albitar, M., 1976
 Albores-Saavedra, J., 508
 Alcock, R. A., 1893
 Aldrich, W., 2646
 Aledo, A., 2117
 Alessi, C., 116
 Alexander, E. E., 123
 Alfson, G. C., 1291
 Algan, Ö., 399
 Allen, J., 2587
 Allen, P. K., 1371
 Allred, D. C., 2145
 Allsbrook, W. C., Jr., 1818
 Althuis, M. D., 800
 Álvarez, M. P. L., 1706
 Amadori, D., 1145
 Amato, R., 615
 Ameshima, S., 1448
 Amin, M. B., 604
 Amorosi, A., 1205
 Anda, T., 2292
 Anderson, B., 1402, 1520
 Anderson, B. O., 2187
 Anderson, H., 741
 Anderson, P. R., 2565

Andersson, R., 1495
 Angeles, C., 2169
 Anongba, D., 653
 Anton-Culver, H., 1883
 Antonescu, C. R., 783, 793
 Antonopoulos, M. J., 774
 Antonuzzo, A., 1714
 Aoyama, T., 1561
 Apollonio, L., 297
 Apostolaki, S., 1380
 Arai, C., 1611
 Arai, T., 35
 Arat, M., 1474
 Arima, M., 1677
 Arita, K., 1102
 Arnoldi, E., 1145
 Arnone, P., 2038
 Asakura, H., 842
 Asano, S., 551
 Asao, T., 2560
 Asaumi, K., 1466
 Ascierto, P. A., 1490, 2630
 Ashkan, K., 1111
 Ashley, S. E., 2145
 Avellini, C., 297
 Avenaud, P., 1431
 Avital, S., 1692
 Ayala, A. G., 995
 Aydin, Z. D., 12
 Azinovic, I., 2622

B

Baba, M., 1214
 Babaian, R. J., 1800
 Bacci, G., 1961
 Bachter, D., 236
 Baek, M. J., 60
 Baekelandt, M., 2076
 Bagnulo, S., 1396
 Bajetta, E., 763
 Balabaud, C., 1431
 Balda, B.-R., 236
 Balibrea, J.-L., 1220
 Balm, A. J. M., 1195
 Bamberg, M., 192
 Bane, B. L., 412
 Banerjee, M., 404
 Bang, S.-M., 2521
 Bang, Y.-J., 2521
 Bankoff, M., 1946
 Barakat, R. R., 383
 Barista, I., 12

Barnadas, A., 2169
 Baron, J. A., 165
 Barón, M. G., 1706
 Barron, B., 104
 Barsky, S. H., 1512
 Barton, D. P. J., 834
 Barton, J. H., 328
 Basil, J. B., 1758
 Baulieux, J., 946
 Bayer, L., 2117
 Beger, H. G., 288, 1440
 Bekkenk, M. W., 913
 Beksaç, M., 1474
 Bell, W. C., 171
 Belón, J., 1706
 Belt, R. J., 597
 Beltrami, C. A., 297
 Benhamiche, A. M., 757
 Benito, M., 1220
 Ben-Yosef, R., 1037
 Berd, D., 1561
 Bergé, S., 1659
 Bergh, A., 1315
 Berkman, L. F., 2176
 Berlin, N. I., 2349
 Berrino, F., 893
 Bertuccelli, M., 1714
 Berwick, M., 342
 Bescos, S., 939
 Bianco, A. R., 1065
 Bidoli, P., 763
 Birckbichler, P. J., 412
 Bisogna, M., 2153
 Bisogno, G., 1396
 Bissonette, E. A., 424
 Biswas, D., 404
 Blacklow, R. S., 1349
 Bladström, A., 741
 Blaise, D., 2138
 Blaszkowsky, L., 1946
 Bleck, O., 1835
 Bleehe, N. M., 1359
 Blum, R., 1953
 Bodoky, G., 177
 Bonifazi, V., 1714
 Bonner, R. B., 412
 Booser, D., 2195
 Boot, H., 2214
 Borgen, P. I., 2153
 Bostwick, D. G., 123
 Botnick, L. E., 574
 Bowers, B., 1012

Boyd, C. J., 901
 Boyd, J., 383
 Brachner, A., 2613
 Bradof, J. E., 328
 Brady, M. S., 342
 Brandeis, J., 1792
 Brazovsky, E., 1692
 Brecht, M.-L., 881
 Breiter, S. N., 1569
 Breivald, M., 1495
 Brennan, M. F., 2237
 Bresadola, F., 297
 Brice, P., 647
 Bristow, R. E., 1532
 Brock, P., 1845
 Brölmann, H. A. M., 1765
 Brown, C. C., 1349
 Brown, J., 1845
 Brown, J. K., 881
 Bruckner, H., 314
 Brufman, G., 1037
 Brugarolos, A., 2622
 Bruns, C. J., 488
 Bucana, C. D., 488
 Buch, T., 1783
 Buchmann, J., 2161
 Buckley, J. D., 2315
 Buettner, P. G., 1269
 Buller, R. E., 1402, 1520, 2006
 Bullimore, J., 1359
 Bureau, G., 523
 Burg, G., 1835
 Burger, P. C., 1569
 Burns, D. M., 2506
 Burris, H. A., III, 328, 2655
 Bush, T. L., 800
 Butler, J., 1883
 Butler-Manuel, S. A., 834
 Buttery, L. D. K., 834
 Butzer, U., 288
 Buzdar, A. U., 2195
 Byrd, D. R., 2187
 Byrne, C., 2046
 Byun, J. H., 2521

C

Cady, B., 1, 202
 Calpena, R., 21
 Calvano, J. E., 2153
 Calvo, E., 2622
 Camarasa, M. V., 21
 Canavese, A., 2038
 Canpinar, H., 12
 Caparroz, C., 2301
 Capelli, G., 2247
 Capocaccia, R., 893
 Caraceni, A., 1145
 Caracò, C., 1490

Carli, M., 1396, 2661
 Caro, J. J., 2502
 Carson, B. S., 1569
 Carvalho, G. F., 1308
 Casado, A., 2169
 Casak, S. J., 690
 Casale, F., 1396
 Casey, A. T. H., 1111
 Cassady, J. R., 399
 Castello, G., 1490
 Castro, P. C., 2301
 Catalona, W. J., 1308
 Cavazzini, L., 2025
 Cecchetto, G., 1396
 Ceha, H. M., 2222
 Cellerino, R., 2630
 Cerdán, J., 1220
 Ceresoli, G. L., 89
 Cesarman, E., 445
 Chadburn, A., 445
 Chan, A. T. C., 543
 Chan, C.-Y., 1976
 Chan, J. K. C., 664
 Chandler, S., 920
 Chaney, A. W., 1502
 Chang, H. M., 2521
 Chang, J., 2145
 Chang, K. S. S., 2274
 Chang, V. T., 1162
 Chang, Y.-H., 2274
 Chapman, J. D., 2018
 Chargui, J., 589
 Chau, G.-Y., 983
 Chen, H.-J., 2092
 Chen, J.-S., 750
 Chen, M. E., 1800
 Chen, M. H., 769
 Chen, M.-H., 1810
 Chen, T.-C., 2274
 Chen, V. W., 1349
 Chendil, D., 1893
 Cherchi, P., 1773
 Cheung, N.-K. V., 2122
 Chi, C.-W., 983
 Chi, K.-H., 29
 Chinoy, R. F., 868
 Chizuka, A., 1611
 Cho, C.-L., 2092
 Cho, N. H., 673
 Choe, J.-G., 1371
 Choe, K. J., 2521
 Choi, E. K., 673
 Choi, P. C. L., 467, 664
 Choi, W. H., 2106
 Chou, C., 1634
 Christos, P. J., 342
 Chu, K. U., 574
 Chuang, S.-S., 1586

Chuang, T.-Y., 453
 Chung, Y.-H., 977
 Cittadini, A., 2247
 Ćizmić, A., 932
 Clahsen, P. C., 1748
 Clark, J., 534
 Cleary, K. R., 1252
 Cleeland, C. S., 1634
 Cochran, A. J., 236
 Coebergh, J.-W. W., 1121
 Cohen, S. R., 1854
 Cohn-Cedermark, G., 348, 1495
 Coit, D. G., 342
 Colditz, G. A., 2046, 2176
 Coleman, E., 1019
 Coleman, J. J., III, 453
 Colomer, R., 2169
 Comella, G., 2630
 Comella, P., 2630
 Connolly, J. L., 2046
 Constenla, M., 1706
 Conte, P. F., 1714
 Conticini, L., 1961
 Cooperating Members of the
 European Organization for
 Research and Treatment of
 Cancer Breast Cancer
 Cooperative Group, 1748
 Cooperman, A., 314
 Cornwell, P. E., 171
 Cortes, J., 1976, 2622
 Coscio, S., 116
 Cossu, A., 1773
 Cox, J. D., 1371
 Crandon, A. J., 391
 Crawford, E. D., 597
 Criscuolo, M., 2247
 Cruse, C. W., 236
 Cui, H., 399
 Cui, N.-J., 242
 Cunningham, M. P., 202
 Currie, E. J., 285
 Cuzick, J., 2397
 Czerniak, B., 995
 Czernobilsky, B., 2053

D

Dabouis, G., 523
 D'Acquisto, M., 1065
 Daliani, D., 615
 Dalkin, B., 399
 Daly, B. D. T., 1946
 Damber, J.-E., 1315
 D'Amico, A. V., 1810
 Danenberg, K. D., 288
 Danenberg, P. V., 288
 Dannenberg, A. J., 2637
 D'Antonio, G., 690

Dan'ura, T., 1992
 Daponte, A., 1490, 2630
 D'Armiento, M., 1065
 D'Arrigo, C., 1111
 Davis, D. W., 488
 Dayton, C. M., 445
 de Alava, E., 783, 793
 De Camargo, B., 1845
 De Candis, D., 763
 Decarli, A., 1205
 de Castro, J., 1706
 De Conno, F., 1145
 Dedrick, R. L., 2465
 De Gaetani, C., 2247
 de Irala, J., 2622
 de Juan, C., 1220
 de Kerviler, E., 647
 de la Roche de Bransat, E., 946
 De Laurentiis, M., 1065
 del Campo, J. M., 939
 DeLena, M., 2630
 del Giglio, A., 2301
 de Llorens, R., 1252
 Dell'Oro, S., 89
 De Luca, L. M., 2465
 Demura, Y., 1448
 Dennis, T. D., 181
 Denny, L., 826
 Denoux, Y., 1748
 De Placido, S., 1065
 de Rijke, J. M., 1121
 De Rosa, G., 1065
 Dershaw, D. D., 2538
 Dessole, S., 1773
 de Toffoli, G. K., 116
 de Torres, I., 152
 Detterbeck, F. C., 534
 DeVries, A., 873
 de Vries, E. G. E., 1726
 Dhingra, K., 2195
 D'Horpock, A., 653
 Diakomanolis, E., 1547
 Dieckmann, K., 1322
 Diederich, S., 2457, 2483
 Dietel, M., 187
 Di Giacomo, C., 2247
 Di Giorgio, A., 2038
 Dijkhuizen, F. P. H. L. J., 1765
 Dimopoulos, M. A., 1547
 Diomande, M., 653
 Dionigi, G., 2345
 Dipetrillo, T. A., 1946
 Disdier, P., 2138
 Di Tullio, M. T., 1396
 Dohchin, A., 482
 Doi, R., 2547
 Doi, T., 303, 1466
 Domchek, S. M., 363

Dominioni, L., 2329, 2334, 2345,
 2422
 Dorant, E., 630
 Dorta, J., 1706
 Dosaka-Akita, H., 334
 Dosios, T., 774
 Dowset, M., 2145
 Drach, G., 399
 Drotman, M., 2538
 Du, W., 431, 1917
 Ducerf, C., 946
 Dudeck, J., 192
 Dudhat, S. B., 868
 Duigou, F., 1748
 Dummer, R., 1835
 Dunkel, I. J., 2117
 Dunmore-Griffith, J., 561
 Dunnwald, L. K., 2187
 Duska, L. R., 1532

E

Eary, J. F., 2187
 Ebert, W., 2282
 Echimane, A. K., 653
 Eckhardt, S., 177
 Edelson, M. I., 2053
 Edge, S., 561
 Edwards, B. K., 1349
 Egashira, A., 1413
 Egawa, C., 1732
 Eguchi, K., 2485
 Einarsson, R., 83
 Elgamal, A.-A., 135
 Elias, L., 597
 Ellis, L. M., 488
 Elsaied, A. R., 1976
 Ely, S. A., 445
 Emanuelsson, M., 1315
 Engstrom, M. C., 1634
 Epstein, J. B., 2258
 Epstein, J. I., 1818, 2577
 Eraso, A., 939
 Erland, J. B., 2655
 Estey, E., 1976
 Estrov, Z., 1976
 European Lung Cancer Working
 Party, 523
 Everett, J. R., 356

F

Fabris, C., 297
 Facco, M., 1259
 Faderl, S., 1482, 1976
 Faivre, J., 757
 Fakih, A. R., 868
 Fan, A. C., 769
 Fan, S.-T., 500
 Farinati, F., 2266

Farshid, G., 2527
 Fassoulas, C., 1933
 Fast, D., 1134
 Feakins, R. M., 1684
 Federici, M. G., 383
 Feith, M., 1874
 Feldman, A. L., 1181
 Feliu, J., 1706
 Fernandez-Hildago, O., 2622
 Ferragut, J. A., 21
 Ferrante, J. M., 2202
 Ferrero, A., 116
 Ferretti, S., 2025
 Feuerman, M., 1162
 Fiebigler, W., 890
 Fiebigler, W. C. C., 516
 Field, J. K., 1933
 Figlin, R. A., 597
 Finkelstein, D. M., 363
 Finlay, J. L., 2117
 Fischer, B., 2161
 Fischer, C., 1089
 Fisher, P. G., 1569
 Fisher, S., 1019
 Fishman, E. K., 1532
 Flaherty, L. E., 431
 Flanagan, R. C., 597
 Fleige, B., 1577
 Flickinger, J. C., 1095
 Flynn, C. E., 1048
 Foer, D. R., 1569
 Fontana, R. S., 2352
 Forman, S. J., 680
 Fosmire, H., 399
 Franke, F. E., 1783
 Frascella, E., 2661
 Frascini, G., 2195
 Fraser, R., 534
 Frazier, M. L., 1252
 Freireich, E. J., 1482
 Fremgen, A. M., 202
 Frija, J., 647
 Fritsch, P. O., 1601
 Frye, D., 2195
 Fryer, A. A., 1012
 Fuerst, A., 1322
 Fujimura, S., 2445
 Fujisawa, K., 2059
 Fujisawa, T., 1457
 Fukui, S., 1026
 Funami, Y., 1677
 Funk, J. O., 1835
 Furuichi, S., 1966
 Furukawa, M., 715
 Furutani, K., 2099
 Futagami, M., 582
 Fuwa, N., 2099

G

Gabizon, A., 1037
 Gadd, M. A., 356
 Gadducci, A., 116
 Gafà, R., 2025
 Galli, L., 1714
 Gallicchio, V. S., 1893
 Gallo, G., 690
 Galvan, S., 1259
 Gan, Y., 463
 Gansauge, F., 1440
 Gansauge, S., 1440
 Garbe, C., 1269
 Garden, O. J., 285
 Gardner, T. A., 424
 Garzon, C., 2622
 Gasser, T., 604
 Gatta, G., 893
 Gavelli, G., 2453
 Geerts, W. H., 640
 Geller, B. M., 369
 George, S. M. C., 1901
 Georgoulas, N., 1547
 Georgoulas, V., 1380
 Gerard, J. P., 946
 Gerbing, R. B., 1150
 Gerken, M., 2613
 Gerstner, N., 1322
 Giampalma, E., 2453
 Gianni, S., 2266
 Giannoudis, A., 1300
 Gika, D., 1547
 Giles, F. J., 1647
 Gill, P. G., 2527
 Gillenwater, J. Y., 2085
 Giralt, J. L., 939
 Giralt, S., 1647
 Gitstein, G., 1692
 Giuliano, A. E., 574
 Giuliano, M., 1396
 Glaser, M. G., 1359
 Glass, E. C., 574
 Glynn, T. J., 2327
 Gnekow, A., 2131
 Godballe, C., 863
 Goehl, J., 1983
 Goff, B. A., 2068
 Gold, K., 561
 Goldberg, R. M., 1699
 Goldenberg, D. M., 104
 Goldman, F. P., 2587
 Goldthwaite, P. T., 1569
 Gollamudi, S. V., 2117
 Gómez, L. L., 1706
 González, D. G., 2222
 Gonzalez, E. C., 2202
 Gonzalez, J., 939
 González-Quevedo, R., 1220

Goodfellow, P. J., 1758
 Goodman, M. T., 376
 Gordon, M. S., 453
 Gorgoulis, V. G., 1933
 Gorsetman, J., 69
 Gorsky, M., 2258
 Gossot, D., 647
 Gotoda, T., 2555
 Gouma, D. J., 2222
 Grado, G. L., 135
 Graells, M. L., 21
 Graf, A. H., 1555
 Granel, B., 2138
 Gravina, A., 2630
 Gray, J. R., 2655
 Grazi, R. V., 1279
 Greco, F. A., 328, 2655
 Grecula, J. C., 2587
 Greenberg, D. B., 356
 Greenberg, R. E., 2018
 Greenberg, R. S., 1349
 Gregor, A., 1359
 Greul, R., 516
 Greulich, K. M., 97
 Griffiths, C. E. M., 1012
 Grizzle, W. E., 171
 Grönberg, H., 1315
 Groome, P. A., 142, 901
 Grosche, B., 2613
 Grote, H.-J., 995
 Guadagnoli, E., 561, 1739
 Guérin, K., 1824
 Guermazi, A., 647
 Guglietta, A., 2258
 Gunji, Y., 1677
 Gunvén, P., 69
 Gurrieri, C., 1259

H

Ha, C. S., 1371
 Habib, G., 2138
 Häckel, C. G., 995
 Hacker, N. F., 391
 Haddad, R., 1692
 Hadley, J., 561
 Hagiwara, A., 1425
 Hägler, G., 1659
 Hainsworth, J. D., 328, 2655
 Hakulinen, T., 893
 Hall, H. I., 1593
 Halle, J., 534
 Halpern, A. C., 342
 Haluska, F. G., 356
 Hama, S., 1102
 Hamaki, T., 1611
 Han, A. C., 2053
 Han, Q.-X., 1512
 Hanks, G. E., 2018, 2565
 Hanlon, A. L., 2018, 2565
 Hansen, H. S., 863
 Hansen, N. M., 574
 Hara, A., 733
 Harkness, W. F., 1111
 Harle, M. T., 1634
 Harlozinska-Szmyrka, A., 83
 Hart, A. A. M., 1195
 Hasebe, T., 35
 Hashimoto, K., 1413
 Hata, A., 1019
 Hatfield, A. K., 1699
 Hayashi, H., 1677
 Hayes, J. T., 453
 Haynes, M. A., 1349
 Hayter, C. R., 142
 He, J., 2606
 Healey, J. H., 783, 793
 Heffess, C. S., 1076
 Heffler, L. A., 1555
 Heilbrun, L. K., 431
 Heimbürger, D. C., 171
 Heintz, A. P. M., 1765
 Heinzerling, L. M., 1835
 Hejna, M., 516
 Heller, G., 2122
 Hemstreet, G. P., III, 412
 Henning, J. M., 1792
 Henry-Amar, M., 1748
 Henschke, C. I., 2/74
 Henshaw, R. M., 2/77
 Henson, D. E., 508
 Heo, D. S., 2521
 Herlin, P., 1748
 Hernandez, B., 376
 Herrington, C. S., 1300
 Herzog, T. J., 1758
 Heshing, D. T. N. I., 1037
 Hicklin, D. J., 74, 488
 Hien, S., 653
 Higashi, T., 2547
 Hilgers, F. J. M., 1195
 Hillen, H. F. P., 1121
 Hirai, H., 1611
 Hirakawa, K., 1285
 Hirohashi, S., 267
 Hiroshima, K., 1457
 Hiura, K., 1966
 Hla, T., 589
 Ho, G. H., 811, 2153
 Hodges, S., 995
 Hoekstra, H. J., 1720, 1726
 Hoelzinger, D. B., 850
 Hohenberger, W., 1983
 Hokita, S., 1214
 Holmes, F. A., 2195
 Holmes, M. D., 2176
 Hölzer, S., 192, 202

Hombach-Klonisch, S., 2161
Homma, H., 303
Hong, M.-H., 242
Hooper, A. T., 74
Horikawa, T., 715
Horshowski, N., 2138
Hortobagyi, G. N., 2195
Horwitz, E., 2565
Horwitz, E. M., 2018
Hosotani, R., 2547
Howell, A., 817
Hsieh, M.-C., 29
Hsu, C.-P., 1004
Huang, S.-N., 2274
Hufnagl, P., 187
Hughes, J. H., 2006
Humphrey, P. A., 1308
Humphreys, G. F., 229
Hundahl, S. A., 192, 202
Hunt, K. K., 1502
Hurst, R. E., 412
Hussain, M., 431
Hutzler, M. J., 2515
Huvos, A. G., 783, 793
Hwang, S. S., 1162
Hynynen, K., 399

I

Iacona, I., 2661
Iannuzzi, C., 1829
Ichimura, K., 1925
Iizasa, T., 1457
Ikeda, K., 1245, 1285
Ikeda, N., 1732
Ilhan, O., 1474
Illersperger, B., 1601
Imamura, M., 5, 1245, 2547
Imamura, Y., 1448
Imoto, S., 1026
Imperatori, A., 2334, 2345
Indelli, M., 1145
Indolfi, P., 1396
Ingvar, C., 1495
Iniesta, P., 1220
Inomata, M., 255, 1418
Inoue, H., 1466, 1992, 2570
Inoue, K., 1245
Inui, T., 2555
Irie, S., 551
Ironsides, J. W., 1359
Isambert, N., 757
Ishibashi, M., 842
Ishikawa, K., 1925
Ishikawa, T., 1285
Ishizaki, T., 1448
Isobe, H., 334
Italian Multicenter Study Group on
Palliative Care, 1145

Ito, M., 724
Ito, Y., 2099
Iwao, K., 1732

J

Jackson, M., 1134
Jäger, A. C., 863
Jager, P. L., 1726
Jahnson, S., 619
Janda, M., 1322
Jaraiz, M. A., 1706
Jawhari, A., 1684
Jaynes, S., 2646
Jelinek, J., 2677
Jelsing, N. C., 2510
Jernvall, P., 1901
Jewell, K. D., 2187
Jiang, X., 123
Johanning, G. I., 171
Johansson, H., 348, 1495
Johnson, D. H., 1953
Johnson, M. E., 995
Johnson, P., 543
Johnson, P. J., 1387
Johnston, D. A., 995, 1800
Jolitz, G., 1999
Jonasch, E., 356
Jones, D., 615
Jones, P. W., 1012
Jönsson, P.-E., 1495
Jouve, J. L., 757
Jukić, S., 932
Jung, H.-J., 60
Jung, S.-H., 453

K

Kadin, M. E., 2315
Kagawa-Singer, M., 696
Kaibara, N., 970
Kainz, C., 1555
Kaisaki, S., 1869
Kakinuma, R., 2485
Kakizawa, K., 1457
Kalman, L. A., 2655
Kalofonos, H. P., 774
Kamachi, M., 334
Kamata, M., 2099
Kami, M., 1611
Kamimura, A., 334
Kamimura, R., 2438
Kamiya, M., 1026
Kanagawa, K., 1026
Kanazawa, T., 1925
Kanda, Y., 1611
Kaneke, M., 2485
Kanis, S., 262
Kantarjian, H., 1482
Kantarjian, H. M., 1647, 1976

Kantoff, P. W., 1824
Kao, J., 1829
Kaplan, H., 1134
Karlsson, M. G., 619
Karpeh, M. S., 2237
Karttunen, T. J., 1901
Kashtan, H., 1692
Kasimis, B. S., 1162
Kato, H., 248, 955
Kato, M., 5
Kato, Y., 1285
Katz, J., 342
Kaufman, D., 1824
Kawachi, I., 2176
Kawaguchi, H., 1413, 1670
Kawai, A., 1466, 1992
Kawakami, Y., 334, 482
Kawamura, M., 589
Kayser, K., 2282
Keating, M. J., 1976
Keeling, J. W., 1845
Kennedy, B. J., 229
Keogan, M., 1019
Kern, W., 1611
Kernan, N. A., 2117
Kerner, J. F., 561
Keus, R. B., 1195
Khan, K. N., 2637
Kherani, A., 1019
Khoo, L., 800
Khurram, R., 2646
Kiefer, L., 314
Kiemeny, L. A. L. M., 1121
Kikkawa, H., 1626
Kikuchi, E., 842
Kim, C. G., 60
Kim, E. E., 1371
Kim, H., 60
Kim, J., 2646
Kim, J. A., 977
Kim, J. W., 673
Kim, N.-G., 60
Kim, N. K., 2521
Kim, S. R., 2521
Kim, S. W., 2106
Kim, W. S., 2106
Kim, Y. T., 673
Kimura, Y., 2099
King, T. C., 769
Kiosses, E., 1547
Kishi, T., 925
Kishimoto, H., 2597
Kitange, G., 2292
Kitano, S., 255, 1418
Kittas, C., 1933
Klastersky, J., 523
Klee, D., 262
Klein, M., 1555

Klittich, W. S., 2502
 Klonisch, T., 2161
 Kluin, P. M., 2667
 Kluin-Nelemans, H. C., 2667
 Knaani, J., 46
 Knast, W., 83
 Knauf, A. G., 1783
 Knost, J. A., 1699
 Knowles, D. M., 445
 Knudsen, K. A., 2053
 Ko, J. H., 673
 Ko, Y. H., 2106
 Kobayashi, R., 1910
 Kobayashi, S., 1425, 1677
 Kobayashi, T., 963, 2438, 2485
 Koç, H., 1474
 Kodaira, T., 2099
 Kogire, M., 2547
 Koh, T., 1236
 Kohno, H., 1457
 Kohno, T., 2497
 Koike, M., 724, 1026
 Koki, A. T., 2637
 Kokotas, S., 1933
 Kokudo, N., 1869
 Kollias, J., 2527
 Komaki, R., 1953
 Kondo, H., 2555
 Kondo, T., 2445
 Kondziolka, D., 1095
 Kong, J. S., 1371
 Konishi, J., 2547
 Konishi, R., 1910
 Konno, A., 1664
 Koopal, S. A., 1720
 Koops, H. S., 1720
 Korb, L. J., 135
 Kornblau, S. M., 1976
 Kornek, G. V., 516
 Kornmann, M., 288
 Kortmann, R.-D., 2131
 Kos, J., 2282
 Kos, M., 932
 Koseki, K., 724
 Kosmas, C., 774
 Kosuge, T., 267
 Kotsakis, A., 1380
 Kotsinas, A., 1933
 Koukourakis, M., 1380
 Koutrouvelis, P. G., 2085
 Kowald, E., 1601
 Kozuch, P., 1482
 Kraft, C., 2282
 Krag, D. N., 236
 Krähn, G., 97
 Kramer, K., 2122
 Kreuzer, M., 2613
 Krischer, J. P., 2202

Krishnan, A. Y., 680
 Kristensen, G. B., 1291, 2076
 Kronz, J. D., 1818
 Krook, J. E., 1699
 Krueger, J. E., 508
 Krueger, S., 995
 Krušlin, B., 932
 Krysender, L., 1495
 Kubík, A. K., 2363
 Kubota, A., 2597
 Kubota, K., 963
 Kucuk, O., 431
 Kuehl, J., 2131
 Kugaya, A., 1026, 1172
 Kugler, J., 1699
 Kuhn, L., 826
 Kukitsu, T., 303
 Kunishima, S., 1236
 Kurisu, K., 1102
 Kuroda, J., 1869
 Kurosaki, T., 1883
 Kuroshima, K., 1214
 Kusakabe, T., 303
 Kusano, M., 248
 Kushner, B., 2117
 Kushner, B. H., 2122
 Kusumoto, M., 2485
 Kusunoki, M., 1228
 Kuwano, H., 955, 1670, 2560

L

Lacueva, F. J., 21
 Ladanyi, M., 783, 793
 Lah, T. T., 2282
 Lahousen, M., 1555
 Lai, F. M. M., 467, 664
 Lam, P. B., 369
 Lam, S., 2468
 Lambrou, N. C., 1532
 Lamki, L., 104
 Landoni, F., 116
 Láng, I., 177
 Langenberg, P., 800
 Lantos, P., 1359
 Lanza, G., 2025
 Larsson, O., 348
 Lash, T. L., 1739
 LaTrenta, L. R., 2538
 Law, H. Y., 811
 Lazovich, D., 1999
 Le, N., 2258
 Le Bail, B., 1431
 Le Beau, M. M., 2315
 le Cessie, S., 2667
 Lear, J. T., 1012
 Lecksell, K., 2577
 Lecomte, J., 523
 Leder, G., 288
 Lee, G. C., 977
 Lee, K. H., 2521
 Lee, K. R., 1048
 Lee, S. G., 977
 Lee, S. H., 673
 Lee, S.-Y., 715
 Lee, T. W., 664
 Lee, Y. S., 977
 Leeuw, J. A., 1726
 Lehmann, J., 1089
 Lei, K. I. K., 1387
 Lenzen, H., 2457, 2483
 Leocata, P., 2247
 Leodolter, S., 1555
 leRiche, J. C., 2468
 Leung, C. B., 467
 Leung, D., 783, 793
 Leung, S. F., 543
 Leung, T. W. T., 543
 Lew, D., 597
 Li, C.-Y., 1586
 Li, P. K. T., 467
 Liang, C.-L., 2092
 Liaw, Y.-F., 2274
 Liberman, L., 2538
 Libert, P., 523
 Libutti, S. K., 1181
 Lifschitz-Mercer, B., 2053
 Lillington, L., 881
 Liloglou, T., 1933
 Limentani, S., 534
 Lin, C.-N., 1586
 Lin, H.-L., 983
 Lin, J.-W., 2092
 Lin, Y.-C., 750
 Lindholm, C., 1495
 Line, B., 104
 Link, K. H., 288
 Litchy, S., 328
 Litwin, M. S., 1792
 Liu, C.-L., 500
 Liu, Q., 2606
 Liu, T.-Y., 983
 Liu, W., 488
 Liver Tumour Study Group of the
 International Society of
 Paediatric Oncology (SIOP), 1845
 Livingston, R., 2187
 Livingston, R. B., 1953
 Lluch, A., 2169
 Lo, C.-M., 500
 Lo, S.-S., 29
 Loch, T., 1089
 Logothetis, C., 615
 Lokich, J., 2309
 Longhi, A., 1961
 Lorenzo, J., 1252
 Lotem, M., 1037

Love, C., 453
 Low, J. J. H., 391
 Lu, J.-S., 1512
 Lu, K., 2092
 Lucariello, A., 1065
 Lui, S. F., 467
 Lui, W.-Y., 29, 983
 Lukas, P., 873
 Lukens, J. N., 1150
 Lundell, G., 69
 Lunsford, L. D., 1095
 Lutgendorf, S. K., 1402
 Lyass, O., 1037
 Lynch, J. J., 561

M

Ma, J., 242
 Maartense, E., 2667
 MacAulay, C., 2468
 Mackillop, W. J., 142, 901
 Madhavan, K., 285
 Maeda, M., 5
 Maesawa, S., 1095
 Maestri, I., 2025
 Magaziner, J., 800
 Maggino, T., 116
 Mahoney, M. R., 1699
 Mai, H.-Q., 242
 Maislinger, S., 873
 Maiti, P., 1134
 Makatsoris, T., 1824
 Mäkelä, J., 1901
 Mäkinen, M. J., 1901
 Makino, M., 970
 Makuuchi, M., 963
 Malamos, N. A., 774
 Malawer, M. M., 2677
 Maldonado, J., 939
 Maltoni, M., 1145
 Manca, A., 1773
 Mandard, A. M., 1748
 Mandel, L., 2068
 Mandelblatt, J. S., 561
 Maneo, A., 116
 Manfredi, P. L., 920
 Manfredi, S., 757
 Mangold, L. A., 2577
 Mangray, S., 769
 Mankoff, D. A., 2187
 Mann, K., 192
 Manola, J., 1824
 Manshour, T., 1976
 Månsson-Brahme, E., 348
 Mantsch, H. H., 1134
 Marais, A., 1431
 Mariani, L., 763
 Mariatos, G., 1933
 Mariette, X., 647

Marini, G., 2630
 Marosi, L., 516
 Maroto, P., 2169
 Marras, L. C., 640
 Martinez-Aguillo, M., 2622
 Martinez-Monge, R., 2622
 Masaki, T., 1910
 Masferrer, J., 2637
 Massa, M.-J., 1220
 Massarelli, G., 1773
 Massuti, B., 2169
 Mastrangelo, M. J., 1561
 Masuda, C., 589
 Masuda, N., 955
 Masutani, M., 482
 Matsubara, H., 1677
 Matsubara, T., 1869
 Matsui, E., 2485
 Matsumoto, A., 2099
 Matsumura, S., 2445
 Matsuoka, M., 551
 Matsuyama, T., 1611
 Matteuzzi, M., 2025
 Matthay, K. K., 1150
 Mavromanidakis, E., 1380
 Mayhew, C., 1893
 Mayol, M. J., 21
 Mazzaferri, E., 202
 M'Bra, K., 653
 McCarthy, P. M., 2510
 McClain, R., 424
 McConkey, D. J., 488
 McDuffie, K., 376
 McGrath, J. J., 1946
 McKee, R. F., 202
 McLaughlin, J. K., 165
 McLeod, G. R. C., 1269
 McNeal, J. E., 1056
 Mcneese, M. D., 1502
 Mead, G. M., 1359
 Meadows, A. T., 2315
 Medical Research Council Brain
 Tumour Working Party, 1359
 Medrano, J., 21
 Mégraud, F., 1431
 Meignin, V., 647
 Meijer, C. J. L. M., 913
 Melamed, M. R., 2356
 Melancon, C. H., 2068
 Melchert, F., 262
 Mellemkjær, L., 165
 Melucci, M., 1490
 Melucci, M. T., 2630
 Mendoza, T. R., 1634
 Mensah-Adoh, I., 653
 Merkel, S., 1983
 Meropol, N. J., 561
 Meseguer, A., 152

Metras, D., 2138
 Meyer, T., 1983
 Meyers, P., 793
 Meyers, P. A., 783
 Mezawa, S., 303
 Michael, Y. L., 2176
 Michalas, S., 1547
 Micheli, A., 893
 Miettinen, O. S., 2449
 Migaldi, M., 2247
 Mihatsch, M. J., 604
 Mihm, M. A., 356
 Mikami, I., 1172
 Mikami, T., 733
 Miki, T., 2570
 Miller, A. W., 1349
 Miller, D. S., 1593
 Millikan, R., 615
 Min, H.-Q., 242
 Minato, H., 2438
 Mingazzini, P., 2038
 Mistry, R. C., 868
 Mitchell, W., 534
 Mitomi, H., 733
 Mitsushashi, H., 1448
 Miwa, A., 1611
 Miyakawa, I., 2059
 Miyamori, I., 1448
 Miyanishi, K., 303
 Miyata, M., 1925
 Miyazaki, M., 1413
 Miyazaki, T., 955, 2059
 Miyoshi, Y., 1732
 Moch, H., 604
 Mochiki, E., 2560
 Moe, R. E., 2187
 Mohiuddin, M., 1893
 Mok, T. S. K., 543
 Mol, B. W. J., 1765
 Mölenkamp, G., 2131
 Molina, A., 680
 Möller, T., 741
 Mommen, P., 523
 Montanari, L., 1145
 Monteiro, L., 1431
 Monti, J. E., 232
 Monti, M., 1145
 Montz, F. J., 1532
 Moon, W. S., 2106
 Moore, T., 769
 Mor, V., 1739
 Morales, G., 690
 Morihiro, M., 35
 Morimoto, Y., 1992
 Morin, A., 1220
 Morinaga, N., 2560
 Morita, K., 2099
 Morita, M., 1925

Moriya, Y., 35
 Moriyama, K., 1966
 Moriyama, N., 2485
 Mornex, F., 946
 Morote, J., 152
 Morris, C., 817
 Morris, E. A., 2538
 Morris, M. J., 1329
 Morrissey, L. H., 328
 Morrissey, M., 1634
 Morton, D. L., 236
 Moss, S. M., 2369
 Moss, T. H., 1359
 Motohashi, H., 2237
 Motta, G., 2331
 Moulopoulos, L. A., 1547
 Mount, B. M., 1854
 Movsas, B., 2018
 Mozzillo, N., 1490
 Mueller, J. D., 1874
 Mulcahy, H. E., 1684
 Müller, K. M., 2613
 Mulshine, J. L., 2465
 Münstedt, K., 1783
 Muntz, H. G., 2068
 Murai, M., 842
 Murakami, S., 2438
 Murakata, L., 508
 Murrell, D. S., 1359
 Muss, H. B., 369
 Mutch, D. G., 1758
 Muto, H., 1664

N

Nabeya, Y., 1677
 Naccarato, R., 2266
 Nademanee, A., 680
 Nadir, B. S., 135
 Nagahata, S., 1910
 Nagai, K., 1172
 Nagamura-Inoue, T., 551
 Nagasaka, T., 2230
 Nagata, H., 1664
 Naito, N., 1992
 Naito, S., 2292
 Nakagawa, A., 1150
 Nakagawa, T., 1245
 Nakajima, J., 2497
 Nakajima, T., 955, 1869
 Nakamoto, Y., 2547
 Nakamura, S., 2292
 Nakanishi, T., 1026, 1466
 Nakanishi, Y., 248, 267
 Nakano, T., 1524
 Nakao, A., 2230
 Nakashima, J., 842
 Nakata, B., 1285
 Nakhosteen, J. A., 2494

Nanni, O., 1145
 Napolitano, M., 1490
 Naruke, T., 2485
 Nash, M., 1810
 Nason, K. S., 2187
 Nasu, K., 2059
 Nathan, F. E., 1561
 Natsugoe, S., 1214, 1874
 Nesbakken, A. J., 2076
 Neuber, K., 1835
 Ng, E. H., 811
 Ng, I. O.-L., 500
 Ng, I. S. L., 811
 Nguyen, B., 543
 Nguyen, M., 1512
 Nguyen-Dobinsky, T.-N., 187
 Nicholson, E., 1019
 Nicolás, A., 152
 Niederhagen, B., 1659
 Nielsen, F. C., 863
 Nihei, Z., 724
 Niinobu, T., 276
 Niitsu, Y., 303
 Ninane, V., 523
 Ninfo, V., 1396, 2661
 Nishida, K., 1466
 Nishihira, J., 334
 Nishikawa, H., 1966
 Nishimura, A., 1245
 Nishimura, K., 2570
 Nishino, H., 1285, 1925
 Nishioka, M., 1910
 Nishiwaki, Y., 1172
 Nishiyama, H., 2485
 Nissen, M. J., 1999
 Noda, M., 1228
 Noguchi, K., 2597
 Noguchi, M., 1056
 Noguchi, S., 1732
 Noguchi, Y., 2237
 Noh, D.-Y., 2521
 Nomoto, S., 2230
 Nomura, K., 1541
 Nonomura, A., 2438
 Nonomura, N., 2570
 Noordijk, E. M., 2667
 Norman, S. A., 850
 Nozaki, Z., 2438
 Numata, T., 1664
 Nussler, A. K., 1440

O

Oakes, R., 1893
 Oberley, L. W., 123
 Oberley, T. D., 123
 Obermair, A., 1322
 O'Brien, S., 1482, 1647
 Ochetti, A., 2334, 2345

Ochiai, A., 35
 Ochiai, T., 1677
 Oda, M., 2438
 Offit, K., 383
 Ogata, A., 334
 Ogata, N., 276
 Ogawa, Y., 1285
 Ogura, S., 334
 Oh, W., 1824
 Oh, Y. K., 1371
 Ohara, N., 1466
 Ohba, Y., 1966
 Ohbuchi, T., 334
 Ohe, G., 1966
 Ohigahi, T., 842
 Ohlsén, H., 69
 Ohmatsu, H., 2485
 Ohno, S., 1413, 1670
 Ohta, Y., 2438
 Ohtsuka, T., 2497
 Ohwada, H., 1457
 Ojeda, B., 2169
 Oka, K., 1524
 Oka, T., 963
 Okabayashi, T., 2555
 Okamoto, K., 1425
 Okamoto, M., 1966
 Okamoto, N., 2489
 Okamura, H., 1026, 1172
 Okano, K., 267
 Okazumi, S., 1677
 Oksenhendler, E., 647
 Oku, N., 1626
 Oku, T., 303
 Okuyama, A., 2570
 Olayasu, I., 733
 Oliveria, S. A., 342
 Olsen, J. H., 165
 Olsson, H., 741
 Onaitis, M., 1019
 ONCOPAZ Cooperative Group,
 Spain, 1706
 O'Neill, M. J., 1532
 Ono, H., 2555
 Ono, M., 35
 Ono, S., 2445
 Orlandini, C., 1714
 Ormerod, M., 2145
 Osawa, N., 255
 Osborne, C. K., 817
 Oshikawa, T., 1966
 Oshiro, Y., 995
 Otsuji, E., 1425
 Otsuji, M., 1457
 Ott, M., 356
 Ouchida, M., 1992
 Overholser, J. P., 74
 Oyang, T., 1874

Ozaki, T., 1466, 1992
 Özcan, M., 1474

P

Paesmans, M., 523
 Pagliaro, L., 615
 Pal, N., 2202
 Palcic, B., 2468
 Palli, D., 1205
 Palmieri, G., 1490, 1773, 2630
 Pamias, J., 939
 Panizo, A., 783
 Paolucci, M., 2334, 2345
 Papadimitriou, C. A., 1547
 Pápai, Zs., 177
 Paradiso, J., 314
 Parasole, R., 1490
 Pardo-Mindán, F. J., 783
 Park, C., 60
 Park, J.-H., 60
 Parkin, D. M., 437, 653, 2363, 2369
 Partin, A. W., 2577
 Pashos, C. L., 1792
 Passoni, P., 89
 Paszat, L. F., 142
 Patchett, S. E., 1684
 Patel, N., 1893
 Payne, R., 920
 Pegna, A. L., 1714
 Peker, S., 1835
 Pepe, S., 1065
 Peracaula, R., 1252
 Peraki, M., 1380
 Perez-Vazquez, M. T., 21
 Perilongo, G., 1845
 Perin, A., 1259
 Perrin, L. C., 391
 Perrone, F., 1490
 Perry, J. R., 640
 Peter, R.-U., 97
 Peters, P. E., 2483
 Peters, W. P., 1917
 Peterse, H., 2214
 Petracchi, S., 1961
 Petroni, G. R., 424
 Petruzzelli, S., 1714
 Petty, T. L., 2461
 Phang, B. H., 811
 Philips, A., 1845
 Phoa, S. S. K. S., 2222
 Piao, Z., 60
 Piazza, F., 1259
 Pierce, S., 1976
 Piers, D. A., 1720, 1726
 Pietsch, T., 2131
 Pigazzi, A., 920
 Pijpers, R., 236
 Pillasch, J., 288

Pinkenburg, F. A., 1089
 Pinover, W., 2565
 Pinover, W. H., 2018
 Pintus, A., 1773
 Pirastu, M., 1773
 Pirisi, M., 297
 Pisano, M., 1773
 Pisters, P. W. T., 1502
 Pitha, J. V., 412
 Pitot, H. C., 1699
 Piva, L., 1145
 Piyathilake, C. J., 171
 Pizzolo, G., 1259
 Placke, M. E., 2465
 Planck, M., 741
 Plaschkes, J., 1845
 Plukker, J. Th. M., 1720
 Polak, J. M., 834
 Pollack, A., 826, 1502
 Poller, I., 177
 Pollock, R. E., 1502
 Polyzos, A., 774
 Poon, R. T.-P., 500
 Porcu, E., 1961
 Postma, T. J., 913
 Pötter, R., 1322
 Potter, S. R., 2577
 Pourat, N., 696
 Powles, T. J., 2145
 Pozzi, P., 763
 Pradhan, M., 2527
 Preciado, M. V., 690
 Prewett, M. C., 74
 Pritchard, J., 1845
 Procopio, G., 763
 Prost, P., 757
 Prout, G. R., Jr., 1349

Q

Qi, K., 574
 Qian, J., 123
 Quaglia, A., 1684

R

Rader, J. S., 1758
 Raderer, M., 516, 890
 Ragde, H., 135
 Rahóty, P., 177
 Ramachandran, S., 1012
 Ramjiawan, B., 1134
 Ramon y Cajal, T., 2622
 Ramos, C. G., 1308
 Rampling, R. P., 1359
 Raslawski, E., 690
 Raspall, G., 939
 Rauws, E. A. J., 2222
 Redhead, D. N., 285
 Redman, B., 431

Ree, H. J., 2106
 Reich, R. H., 1659
 Reiners, C., 192
 Reinthaller, A., 1555
 Renshaw, A. A., 1810
 Retz, M., 1089
 Rhoades, C. A., 2587
 Rhodes, S. N., 850
 Ricci, S., 1714
 Richie, J. P., 1810
 Ries, L. A. G., 893
 Rinaldi, M., 2266
 Ringborg, U., 348, 1495
 Rivera, E., 2195
 Rivera, M. P., 534
 Rivkin, S. E., 597
 Robboy, S. J., 1349
 Roberts, J. T., 1359
 Robinett, F. D., 2377
 Robison, L. L., 2315
 Robson, M. E., 383
 Rodger Winn for the Outcomes and Preferences for Treatment in Older Women Nationwide Study (OPTIONS) Research Team, 561
 Rodriguez, J., 2622
 Roessner, A., 995
 Roetzheim, R. G., 2202
 Rogalla, P., 1577
 Rogers, J. D., 1593
 Rohrer, M. J., 2515
 Rosai, J., 202
 Rosato, E. L., 1561
 Rosato, F. E., 1561
 Rose, M., 881
 Rosen, A. C., 1555
 Rosen, P. P., 2153
 Rosenblum, N. G., 2053
 Rosenman, J. G., 534
 Rosolen, A., 2661
 Rothmund, M., 192
 Rothrock, N., 1402
 Rovera, F., 2334, 2345
 Rozen, P., 46
 Rückert, R. I., 1577
 Rudén, B.-I., 69
 Ruggiero, A., 1065
 Ruii, G., 1773
 Rumpold, G., 873
 Rush, D., 2637
 Russo, A., 1205
 Russo, S., 534
 Rutqvist, L. E., 348, 1495
 Ryan, B. F., 356

S

Sackmann-Muriel, F., 690
 Saeki, H., 1413, 1670

- Safran, H., 769
 Sagawa, M., 2445
 Sage, P. B., 1431
 Sahmoud, T. M., 1748
 Saieva, C., 1205
 Saigo, P. E., 383
 Saito, D., 2555
 Saito, Y., 582, 2445
 Saitoh, Y., 1457
 Sakahara, H., 2547
 Sakamoto, M., 267
 Sakamoto, T., 582
 Sakr, W., 404
 Sakurada, A., 2445
 Sakurai, K., 2597
 Salazar, H., 2053
 Salomaa, E.-R. M., 2387
 Salonga, D., 288
 Salvini, S., 1205
 Sammartino, P., 2038
 Samuel, Z., 46
 Sánchez-Pernaute, A., 1220
 Sandomenico, C., 1065
 Sankaranarayanan, R., 437, 475
 Sano, H., 589
 Sant, M., 893
 Santana, V. M., 463
 Santella, R. M., 123
 Santini, A., 2025
 Santoro, N., 1396
 Sanz, X., 939
 Sargent, D. J., 1699
 Sarna, L. P., 881
 Sarra, E., 1380
 Sartori, E., 116
 Sarun, S., 2161
 Sasaki, S., 35
 Sasako, M., 2555
 Sasaoka, M., 2099
 Sato, F., 5
 Sato, K., 1418
 Sato, M., 1966, 2445
 Sato, S., 582
 Sato, T., 1561
 Sause, W., 1953
 Sauter, G., 604
 Savarese, D. M. F., 2515
 Scarpini, M., 2038
 Schanzenbächer, U., 2282
 Scheck, A. C., 850
 Scheithauer, W., 516, 890
 Schell, M. J., 534
 Scher, H. I., 1329
 Schlosser, S., 1440
 Schmidt, R. A., 2187
 Schmuth, M., 1601
 Schneebaum, S., 1692
 Schneeweiss, B., 516
 Schneider, C. J., 2222
 Schnelldorfer, T., 1440
 Schnitt, S. J., 2046
 Schouten, L. J., 1121
 Schreeder, M. T., 2655
 Schuller, D. E., 2587
 Schulman, K. A., 561
 Schulze, K., 142
 Scopinaro, M., 690
 Scott, C., 297
 Sculier, J. P., 523
 Sedlacek, P., 83
 Seeger, R. C., 1150
 Seiden, M., 1824
 Seiden, M. V., 363
 Seigler, H. F., 1019
 Seiwerth, S., 932
 Seki, H., 482
 Seki, T., 1245
 Seldin, D., 104
 Selhub, J., 376
 Semenzato, G., 1259
 Semik, M., 2483
 Sepp, N. T., 1601
 Seppelt, U., 1089
 Sepsas, E., 774
 Serafini, A., 104
 Sergysels, R., 523
 Serratrice, J., 2138
 Sexton, M., 800
 Sgambato, A., 2247
 Shafford, E., 1845
 Shah, J. P., 202
 Shaheen, R. M., 488
 Shahin, M. S., 2006
 Shakunaga, T., 1466
 Shan, A., 123
 Shao, Z.-M., 1512
 Shapiro, J. R., 850
 Sharma, P., 2587
 Sheen, T.-S., 715
 Shen, K.-H., 29
 Shen, K.-W., 1512
 Shen, Z.-Z., 1512
 Shiba, K., 1664
 Shiba, M., 1457
 Shibamoto, Y., 53
 Shibata, S., 2292
 Shibata, T., 276
 Shields, A. F., 1917
 Shields, C. L., 1561
 Shields, J. A., 1561
 Shimada, H., 1150, 1677
 Shimada, Y., 5
 Shimizu, K., 1992
 Shimoda, T., 35, 248, 2555
 Shimura, T., 2560
 Shin, E.-C., 60
 Shindoh, M., 334
 Shiraishi, N., 255, 1418
 Shiroto, H., 482
 Shitara, Y., 955
 Shmookler, B. M., 1279, 2677
 Shouji, H., 955
 Shue, M. J., 2577
 Siegel, S., 2315
 Siewert, J. R., 1874
 Silberman, M. A., 1818
 Silliman, R. A., 1739
 Singh, R., 123
 Siviero, M., 1259
 Sixbey, J. W., 463
 Skoog, L., 69
 Skornick, Y., 1692
 Skovlund, E., 1291
 Slesak, B., 83
 Smith, A. G., 1012
 Smith, M. R., 1824
 Smith, R. A., 2327
 Smith, R. E., 2587
 Smith, T., 615
 Smyczynski, M. S., 2515
 Snady, H., 314
 Sniecinski, I., 680
 Snijder, S., 2667
 Soares, H. P., 2301
 Sober, A. J., 356
 Sobue, T., 2392
 Socinski, M. A., 534
 Sokoloff, M. H., 424
 Soldà, M., 116
 Soler, A. P., 2053
 Söllner, W., 873
 Song, B.-C., 977
 Sonis, S. T., 2258
 Soo, K. C., 811
 Sood, A. K., 1402, 1520, 2006
 Sørensen, H. T., 165
 Sorosky, J. I., 1402, 1520
 Soslow, R. A., 2637
 Souglakos, J., 1380
 Souquet, J. C., 946
 Spiess, E., 2282
 Spinetti, G., 116
 St. John, T. M., 2377
 Staibano, S., 1065
 Stamey, T. A., 1056
 Stani, S. C., 763
 Starz, H., 236
 Stea, B., 399
 Steen, J., 1783
 Steffensen, F. H., 165
 Stein, H. J., 1874
 Steixner, E., 873
 Stenning, S. P., 1359
 Stewart, A. K., 192, 202

Stobbe, C., 2018
 Stock, R. G., 1829
 Stöckle, M., 1089
 Stone, N. N., 1829
 Stram, D. O., 1150
 Strange, R. C., 1012
 Strauss, G., 2502
 Strauss, G. M., 2329, 2399, 2422, 2432
 Sugao, H., 2570
 Sugarbaker, D. J., 2432
 Sugarbaker, P. H., 1279
 Sugihara, K., 724
 Sugimachi, K., 1413, 1670
 Sugimoto, H., 2230
 Sugimoto, K., 1910
 Sugitoh, M., 35
 Sugiyama, K., 1102
 Suguro, M., 1611
 Suh, D. J., 977
 Sullivan, C. L., 104
 Sunelaitis, E., 288
 Sungur, A., 12
 Sunny, L., 437
 Šupran, S., 1946
 Suzuki, J., 482
 Suzuki, K., 970
 Suzuki, T., 1677
 Suzuki, Y., 1524
 Swaminathan, R., 437
 Świader, L., 2138
 Szántó, J., 177
 Szendrői, M., 177
 Szeto, C. C., 467

T

Taal, B. G., 2214
 Tachibana, M., 842
 Tachimori, Y., 248
 Tai, D.-I., 2274
 Tai, Y., 1910
 Tajima, K., 955
 Tajima, Y., 248
 Takada, K., 303
 Takagi, I., 53
 Takaha, N., 2570
 Takahashi, H., 2445
 Takahashi, T., 1869
 Takahashi, Y., 2597
 Takai, N., 2059
 Takami, M., 276
 Takamoto, S., 2497
 Takao, S., 1214
 Takeda, A., 1677
 Takezako, N., 1611
 Takigawa, M., 1466
 Takizawa, T., 724
 Talpaz, M., 1482, 1647

Tamai, T., 1245
 Tamaki, N., 2547
 Tamura, N., 1910
 Tan, F. E. S., 630
 Tan, I. B., 1195
 Tan, L. K., 2153
 Tanabe, G., 1214
 Tanabe, K. K., 356
 Tanaka, Y., 925
 Tanda, F., 1773
 Tang, K., 1800
 Tani, K., 551
 Taniguchi, H., 1236
 Taniguchi, T., 970
 Tanita, T., 2445
 Taylor, D. C., 2577
 Tekuzman, G., 12
 Tempfer, C. B., 1555
 Terada, N., 1664
 Terai, K., 1966
 Teruel, A., 21
 Tezel, E., 2230
 Thaler, H. T., 1162
 Theodorescu, D., 424, 2085
 Theriault, R. L., 2195
 Theuer, C. P., 1883
 Thiriaux, J., 523
 Thomas, D. A., 1976
 Thomas, D. G. T., 1111
 Thomas, M., 2483
 Thompson, L. D. R., 1076
 Thompson, M. E., 597
 Thompson, T. P., 1095
 Thoresen, S. Ø., 1291
 Thorson, P., 1308
 Thulstrup, A. M., 165
 Tibaldi, C., 1714
 Tiebosch, A. T. M. G., 1720
 Tihan, T., 1569
 Timm, K. J., 1089
 Tkaczuk, K., 800
 To, K. F., 467, 664
 Tockman, M. S., 2465
 Toda, G., 53
 Todesco, A., 2661
 Togawa, A., 1611
 Tojo, A., 551
 Tokuda, M., 1910
 Toma, A., 1425
 Tomičić, I., 932
 Toniutto, P., 297
 Topar, G., 1601
 Torhorst, J., 604
 Torres, A., 1220
 Torrigiotti, G., 2334
 Tørring, H., 863
 Touchette, D., 1917
 Trentin, L., 1259

Tresurywala, S., 850
 Trimble, E. L., 1532
 Triozzi, P. L., 597, 2646
 Trivedi, C., 431
 Trocha, C., 1089
 Troitsa, A., 1692
 Troncoso, P., 1800
 Tropé, C. G., 2076
 Tsai, S.-L., 2274
 Tsavaris, N. B., 774
 Tseng, H.-S., 29
 Tsoli, E., 1933
 Tsubouchi, Y., 589
 Tsuburaya, A., 2237
 Tsukada, H., 1626
 Tsukada, K., 955
 Tsukamoto, F., 1732
 Tsunoda, K., 2292
 Tsuruta, O., 733
 Tsutsumi, S., 2560
 Tu, S.-M., 615
 Turner, R. R., 574
 Turrisi, A. T., 1953
 Tyler, D. S., 1019

U

U.S. and German Thyroid Cancer Group, 192
 U.S. and German Thyroid Cancer Study Group, 202
 Uchida, C., 1869
 Uchitomi, Y., 1026, 1172
 Ueda, K., 925
 Ueda, M., 1869
 Uhler, R. J., 1593
 Ukimura, S., 2570
 Ulrich-Pur, H., 516
 Umehara, S., 1150
 Unger, P., 1829
 Urade, M., 2597
 Urbanek, M., 1835
 Utikal, J., 97
 Uziely, B., 1037
 Uzzau, A., 297

V

Vacek, P. M., 369
 Vadiaka, M., 774
 Vaitkevicius, V. K., 1917
 Valero, V., 2195
 Van Cutsem, O., 523
 van Dalen, A., 83
 van den Brandt, P. A., 630, 1121
 van den Broek, L., 1748
 van der Graaf, W. T. A., 1726
 Vander Poorten, V. L. M., 1195
 van de Velde, C. J. H., 1748
 van de Vijver, M. J., 1748

Van Durme, D. J., 2202
 van Tienhoven, G., 2222
 Van Zee, K. J., 2153
 Varughese, T., 868
 Veenhof, C. H. N., 2222
 Venkateswaran, L., 463
 Ventura, L., 2247
 Verdecchia, A., 893
 Versari, M., 1961
 Vey, N., 2138
 Vicent, J. M., 1706
 Vihko, P., 1901
 Vilà, M. R., 152
 Villa, E., 89
 Višnjić, A., 932
 Vlachonikolis, J., 1380
 Vlahos, G., 1547
 Volz, J., 262
 Volz-Köster, S., 262
 von den Driesch, P., 1835
 von Georgi, R., 1783
 von Lindern, J. J., 1659
 Vora, S. A., 1946
 Vos, A., 1845
 Voulgaris, Z., 1547

W

Wachter, S., 1322
 Wada, S., 589
 Wagner, H., 1953
 Wagner, J. D., 453
 Wainwright, H., 826
 Wakeling, A. E., 817
 Waksal, H. W., 74
 Walker, M. J., 2646
 Walsh, P. C., 2577
 Walters, R., 2195
 Wang, A. Y. M., 467
 Wang, C.-H., 750
 Wang, H.-M., 750
 Wang, X. S., 1634
 Watanabe, G., 5
 Watanabe, H., 248
 Watanabe, M., 1413
 Watanabe, S.-i., 2438
 Watanabe, Y., 2438
 Watari, K., 551
 Webster, R., 2465
 Weeks, J. C., 561
 Wegener, W. A., 104
 Wei, G., 793
 Wei, J. T., 232
 Weiller, P.-J., 2138
 Weingart, J. D., 1569
 Weinstein, R. S., 1349
 Weir, H. K., 1593

Welker, J. A., 2677
 Wellek, S., 1089
 Wenngren, E., 741
 Werle, B., 2282
 Werner, M., 1874
 Wesley, M. N., 1349
 Westphal, S., 2131
 Wewers, M. E., 881
 Whaley, J. B., 1359
 Wharam, M. D., 1569
 Wichmann, H.-E., 2613
 Wiethage, T., 2613
 Wigmore, S. J., 285
 Wilkens, L. R., 376
 Willemze, R., 913
 Williams, J. A., 1569
 Wilson, M. R., 488
 Woerner, B. M., 2637
 Wolff, J. E. A., 2131
 Wong, J., 500
 Wood, D. P., Jr., 404, 597
 Woodruff, J. M., 1577
 Wormanns, D., 2483
 Wrba, F., 890
 Wright, T. C., Jr., 826
 Wu, C.-W., 29
 Wu, J., 1512
 Wu, M., 2606
 Wu, Y., 1810

X

Xiangming, C., 1214

Y

Yamada, Y., 551
 Yamagishi, H., 1236, 1425
 Yamaguchi, A., 1236
 Yamaguchi, H., 248
 Yamaguchi, S., 2570
 Yamamoto, J., 267
 Yamamoto, R., 1611
 Yamamoto, S., 267
 Yamamura, T., 1228
 Yamasaki, F., 1102
 Yamasaki, S., 5
 Yamashiki, N., 1245
 Yan, H., 1279
 Yan, T., 123
 Yan, Y., 1308
 Yanagi, H., 1228
 Yanagisawa, A., 1869
 Yanagisawa, N., 733
 Yang, C.-C., 1004
 Yang, G., 2606
 Yang, J., 2606

Yang, S.-D., 1004
 Yang, T.-S., 750
 Yang, W. I., 673
 Yang, W. T., 543
 Yasoshima, H., 2597
 Yasuda, K., 255, 1418
 Yasunaga, A., 2292
 Yasunaga, Y., 2570
 Yemoto, C. E. M., 1056
 Yeo, W., 543
 Yeole, B. B., 437
 Yeung, R. S., 2187
 Yim, A., 543
 Yim, A. P. C., 664
 Yokoyama, Y., 582
 Yoshida, H., 1966
 Yoshida, S., 2555
 Yoshida, T., 733
 Yoshikawa, M., 955
 Yoshikawa, R., 1228
 Yoshikawa, T., 2237
 Yoshimura, K., 248
 Yoshimura, N., 589
 Yoshimura, R., 589
 Yoshioka, H., 1102
 Yoshizaki, T., 715
 Young, D., 2587
 Younger, J., 363
 Yu, A. W. Y., 467
 Yuen, A. R., 1953

Z

Zabner, R., 680
 Zacharatos, P., 1933
 Zagars, G. K., 1502
 Zagdanski, A.-M., 647
 Zaia, J., 680
 Zakowski, M. F., 2538
 Zambello, R., 1259
 Zatloukal, P., 2363
 Zavarin, M., 2515
 Zee, B., 543
 Zeegers, M. P. A., 630
 Zeniya, M., 53
 Zhang, E.-P., 242
 Zhang, H., 2587
 Zhang, S. H., 1520
 Zhang, Z., 1684, 2606
 Zhang-Salomons, J., 901
 Zhong, W., 123
 Zilembo, N., 763
 Ziogas, A., 1883
 Zola, P., 116
 Zou, G., 1953
 Zubizarreta, P. A., 690